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Abstract

There is heightened interest to diversify the range of crystal forms exhibited by
active pharmaceutical ingredients (APIs) in the pharmaceutical industry. The crystal
form can be regarded as the Achilles’ heel in the development of an API as it directly
impacts the physicochemical properties, performance and safety of the API.

This is of

critical importance since the crystal form is the preferred method of oral drug delivery by
industry and regulatory bodies. The ability to rationally design materials is a lucrative
avenue towards the synthesis of functional molecular solids with customized
physicochemical

properties

such

as

solubility,

bioavailability

and

stability.

Pharmaceutical cocrystals have emerged as a new paradigm in pharmaceutical solid form
development because they afford the discovery of novel, diverse crystal forms of APIs,
generate new intellectual property and modify physicochemical properties of the API. In
addition, pharmaceutical cocrystals are amenable to design from first principles of crystal
engineering.
This dissertation focuses on the crystal engineering of multi-component crystal
forms, in particular pharmaceutical cocrystals and crystalline hydrates. It addresses: (i)
the factors involved in the selection of cocrystal formers (ii) design strategies for APIs
that exhibit complexity, (iii) the role of water molecules in the design of multi-component
crystal forms and (iv) the relationship between the crystal structure and thermal stability
of crystalline hydrates.
viii

In general, cocrystal former libraries have been limited to pharmaceutically
acceptable substances. It was investigated to expand this library to include substances
with an acceptable toxicity profile such as nutraceuticals.

In other words, can

nutraceuticals serve as general purpose cocrystals formers? The model compounds,
gallic acid and ferulic acid, were selected since they possess the functional moieties
carboxylic acids and phenols, that are known to form persistent supramolecular synthons
with complementary functional groups such as basic nitrogen and amides. The result
yielded pairs of cocrystals and revealed the hierarchical nature of hydrogen bonding
between complementary functional groups.
In general, pharmaceutical cocrystals have been designed by determining the
empirical guidelines regarding the hierarchy of supramolecular synthons. However, this
approach may be inadequate when considering molecules that are complex in nature,
such as those having a multiplicity of functional groups and/or numerous degrees of
conformational flexibility.

A crystal engineering study was done to design multi-

component crystal forms of the atypical anti-psychotic drug olanzapine. The approach
involved a comprehensive analysis and data mining of existing crystal structures of
olanzapine, grouped into categories according to the crystal packing exhibited. The
approach yielded isostructural, quaternary multi-component crystal forms of olanzapine.
The crystal forms consist of olanzapine, the cocrystal former, a water molecule and a
solvate.
The role of water molecules in crystal engineering was addressed by investigating
the crystal structures of several cocrystals hydrates and their related thermal stability.
ix

The cocrystal hydrates were grouped into four categories based upon the thermal stability
they exhibit and it was concluded that no structure/stability correlations exist in any of
the other categories of hydrate. A Cambridge Structural Database (CSD) analysis was
conducted to examine the supramolecular heterosynthons that water molecules exhibit
with two of the most relevant functional groups in the context of active pharmaceutical
ingredients, carboxylic acids, and alcohols. The analysis suggested that there is a great
diversity in the supramolecular heterosynthons exhibited by water molecules when they
form hydrogen bonds with carboxylic acids or alcohols. This finding was emphasized by
the discovery of two polymorphs of gallic acid monohydrate to it the first tetramorphic
hydrate for which fractional coordinates have been determined. Analysis of the crystal
structures of gallic acid monohydrate polymorphs revealed that forms I and III exhibit the
same supramolecular synthons but different crystal packing and forms II and IV exhibit
different supramolecular synthons. Therefore, the promiscuity of water molecules in
terms of their supramolecular synthons and their unpredictable thermal stability makes
them a special challenge in the context of crystal engineering.

x

Chapter 1: Introduction
1.1

Relevance of crystal form in pharmaceutical science
The selection of crystal form is a critical step in pharmaceutical development.

Indeed, crystallization is generally used as a separation or purification method in the
production of substances due to its high stability and ease in processing. The vast
majority of active pharmaceutical ingredients (APIs) are isolated in the solid form and the
selection of crystal form is invariably considered to be the first step in formulation
development (Fig. 1.1). Therefore, the control of the crystal form and the size and shape
of the crystal become of paramount interest. The crystal form influences downstream
process applications such as filtration, drying, milling, granulation and tableting. More
importantly, physicochemical properties such as bioavailability, solubility and dissolution
rate are strongly dependent on the crystal form of the API.

Figure 1.1: Steps in the selection of crystal form in the development of the API.

The ubiquitous nature of APIs i.e. they contain multiple hydrogen bonding sites
makes them inherently predisposed to form multiple crystal forms. These crystal forms
include but are not limited to salts, hydrates, solvates, polymorphs and pharmaceutical
1

cocrystals (Fig.1.2). The diversity of crystal forms of an API creates opportunities to
customize the physicochemical properties of that API. High-throughput screening has
been generally used to explore crystal forms of APIs since it accelerates the discovery of
diverse crystal forms and provides an understanding of the factors that govern
crystallization.1 However, in vitro screening in solvents such as dimethyl sulfoxide and
polyethylene glycol to identify as many hits as possible resulted in new drug candidates
exhibiting poor aqueous solubility and/or dissolution rate. 2

As bioavailability is a

function of solubility, poor oral bioavailability has become characteristic of many new
drug candidates. 3,4 In fact, drug candidates with poor bioavailability are the primary
reason why 41% of new drug candidates fail in preclinical and clinical development (Fig.
1.3)5and 90% of new drug candidates fall into BCS class II and class IV (Figure 1.4).6
Therefore, from a crystal engineering perspective, the design of pharmaceutical solids
with desired physicochemical properties becomes relevant.

Fig. 1.2: Schematic representation of the types of crystal forms exhibited by APIs.

2

Figure 1.3: Reasons why new drug candidates fail in development.

Figure 1.4: Comparison of BCS classification of marketed drugs and new drug
candidates.

1.2

Drug Dissolution and Bioavailability
Drug dissolution was first modeled by Noyes and Whitney. They proposed the Noyes

and Whitney equation where the rate of dissolution is proportional to the difference
between the solution concentration at time t and the equilibrium solubility. 7 This
equation was later modified to become the Noyes-Whitney-Nernst equation and denoted
that, with all other parameters being constant, the rate of drug dissolution is proportional
to the thermodynamic solubility of the drug. 8
3

Amidon and coworkers developed the

Biopharmaceutical Classification System (BCS) which proposes that the bioavailability
of the API is a function of solubility or dissolution rate and membrane permeability.9
According to the BCS system, APIs are categorized into four categories:

(1) high

permeability, high solubility; (2) high permeability, low solubility; (3) permeability, high
solubility and (4) low permeability, low solubility (Figure 1.5). A drug substance is
considered highly soluble when the highest dose strength is soluble in < 250 ml water
over a pH range of 1 to 7.5 and highly permeable when the extent of absorption in
humans is determined to be > 90% of an administered dose, based on mass-balance or in
comparison to an intravenous reference dose.

Fig. 1.5: The Biopharmaceutical Classification System (BCS)

4

1.3

Types of Crystal Forms

1.3.1

Hydrates and Solvates
Solvates are molecular complexes where one or more solvent molecules are

incorporated within the crystal lattice in stoichiometric proportions. It is referred to as a
hydrate when the solvent of crystallization is a water molecule. 10 Hydrates represent
about 10% of the structures archived in the CSD 11 and it has been suggested that
approximately 33% of organic compounds form hydrates, whereas solvates are less
prevalent (10%).12 The adventitious nature of the water molecule allows it to be easily
incorporated within the crystal lattice due to its size and versatile hydrogen bonding
capabilities. The water molecule can act as a guest where the water molecule is not
firmly bound within the crystal structure or the water molecule can play an integral role
to stabilize the crystal structure where there is an imbalance in the number of hydrogen
bond and donors.13 APIs are prone to hydrate formation due to their inherent nature, i.e.
they possess many hydrogen bond donors and acceptors and it is estimated that
approximately one third of APIs are capable of forming hydrates during pharmaceutical
manufacturing.14 Stability is a matter of concern for pharmaceutical hydrates because
they can undergo solid phase transition under storage conditions and therefore alter the
physicochemical properties.

1.3.2

Polymorphs
Polymorphism refers to the ability of a compound to exist in more than one

crystal form. The earliest reported polymorphic compound was benzamide discovered in
5

1832 by Wöhler and Liebig. The phenomenon of polymorphism is a scientific challenge
in the pharmaceutical industry and its adverse effects is revealed in the prominent
examples of rantidine hydrochloride and ritonavir.15,16 The relevance of polymorphism
was heightened by the patent litigation between Glaxo and Novopharm, where Glaxo
sued for the infringement of its patent of a form II polymorph of rantidine hydrochloride.
In addition to legal and regulatory implications, polymorphism also affects the
physicochemical properties of an API such as dissolution rate. This is exemplified by the
API ritonavir where after the launch of the drug ritonavir by Abbot Laboratories, a more
stable, previously unknown form II was discovered. The dissolution properties of the
latter were significantly different in comparison to the previous form forcing the
company to reformulate the API resulting in a loss of sales. Polymorphism can be
divided into two classes:

packing polymorphism and conformation polymorphism.

Packing polymorphism occurs when rigid molecules exhibit more than one packing
arrangement caused by different supramolecular synthons or they retain the same
supramolecular synthons but exhibit different crystal packing.

Conformational

polymorphism is when molecules exists in more than one conformation in the solid state
and is exemplified by 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile, ROY
where it crystallizes in eight polymorphic forms.

1.3.3

Salts
Salt formation has been the primary means to modify the physicochemical

properties of an API. Indeed, approximately, 50% of marketed APIs are administered as
salts.17

Salts are formed when a compound that is ionized in solution forms a strong
6

ionic interaction with an oppositely charged counterion. Its success and stability is
dependent on the relative strength of the acid or base and the acidity and basicity constant
of the components involved.18 The general rule of thumb for salt formation is that the
acid ionization constant, pKa, between the acid and the base should be different by at least
two or three units. The limitation of this is that the pKa values are only valid under the
solution equilibrium conditions at which they were determined.

Salt forms are

advantageous because they enhance the physicochemical properties of the API and their
preparation is relatively simple. However, its formation is limited to the presence of
ionizable groups on the API and it compromises the intrinsic activity of the API. In
addition, although hydrochloride salts are the most common anionic salt forming species,
they may not necessarily enhance the solubility in a chloride containing solvent medium
because of common ion effect. For example, the hydrochloride salt of the Prazosin, has
an aqueous solubility of 1.4 mg/ml but 0.037 mg/ml solubility in 0.1M HCl solution.

1.3.4

Pharmaceutical Cocrystal
Pharmaceutical cocrystals, 19 , 20 multi-component crystals in which at least one

component is a neutral API and the cocrystal former is a pharmaceutically acceptable ion
or molecule, have recently been added to the landscape of crystal forms of APIs. Early
literature on pharmaceutical cocrystals focused primarily on the crystal structures of
pharmaceutical cocrystals. Perhaps, the earliest reported pharmaceutical cocrystal is the
1934 French patent which disclosed cocrystals of barbiturates. 21 Caira and others
reported the potential of complexes of sulphonamide drugs in drug development22 and
Whitesides reported the supramolecular assemblies of melamine and babiturates
7

derivatives.23 In 2002, Oswald and coworkers demonstrated the cocrystallization of the
drug paracetamol24 and shortly after, Zaworotko et al reported pharmaceutical cocrystals
of the APIs ibuprofen, flurbiprofen and aspirin. 25 In recent years, pharmaceutical
cocrystals have emerged as a new paradigm in pharmaceutical solid form development as
they are an effective means of altering physicochemical properties such as solubility,
bioavailability and stability of APIs. 26 Indeed, the significant impact of pharmaceutical
cocrystals has resulted in the recent release of a FDA draft guidance concerning the
regulatory classification of pharmaceutical cocrystals.27 The draft proposed the definition
and classification of pharmaceutical cocrystals.
Pharmaceutical cocrystals are advantageous in four-fold because: (1) they are
susceptible to design since the directionality and selectivity of the hydrogen bond allows
for the rational construction of new functional solid forms (2) enables a diverse number
of crystal forms of a given API from a wide range of pharmaceutically acceptable
cocrystal formers and the formation is not limited to the nature of the molecule e.g.
presence of ionizable groups on the API

(3) fine-tunes the structural and

physicochemical properties of the solid and therefore creates intellectual property
opportunities and (4) the intended intrinsic activity of the API is preserved.

8

1.4

Supramolecular Chemistry

Molecular chemistry, thus, has established its power over the covalent bond. The time
has come to do the same over non-covalent intermolecular forces. Beyond molecular
chemistry based on the covalent bond there lies the field of supramolecular chemistry,
whose goal is to gain control over the intermolecular bond.
Jean Marie Lehn28

Supramolecular chemistry, described as “chemistry beyond the molecule”
expands over several science disciplines such as classical inorganic and organic
chemistry, material science and physics. The beginning of supramolecular chemistry can
be traced back to the late 19th century through the introduction of transition-metal
coordination chemistry by Werner,29 Emil Fischer’s lock and key mechanism in enzyme
reactions and the discovery of cyclodextrins by Hebd.

However, it was the pioneering

works of Pederson, 30 Lehn and Cram in the discovery of crown ethers that ignited
interest in supramolecular chemistry. Supramolecular chemistry extends beyond the
realm of atomic and molecular chemistry to afford highly complex, well-defined
supramolecular entities.31 It emphasizes the use of intermolecular interactions in the selfassembly of molecules governed by their chemical and geometrical factors.

9

Intermolecular Interaction

Strength (kJ/mol)

Ion-Ion

100-350

Ion-Dipole

50-200

Hydrogen Bond

4-120

Dipole-Dipole

5-50

π- π Stacking

<50

Van der Waals

<5

Table 1.1: Strength of Non-covalent Interactions.

These intermolecular interactions include hydrogen bonding, π- π stacking,
coordinative bonds, dipolar interactions and van der Waals forces (Table 1.1).32 They
play a critical role in the structure and function of biological systems such as protein
folding and enzyme catalysis.

The hydrogen bond is perhaps the most significant

intermolecular interaction and is fundamental in the stability of the double helix structure
in DNA, the best known self-assembling supramolecular entity in nature. The hydrogen
bond is defined as, “an attractive interaction between a hydrogen atom from a molecule
or a molecular fragment X–H in which X is more electronegative than H, and an atom or
a group of atoms in the same or a different molecule, in which there is evidence of bond
formation.” 33 The hydrogen bond has been extensively studied and is viewed as a
synthetic vector in the structural assembly of molecules. Its strength, selectivity and
directionality influence the crystal packing of molecules thereby determining its physical
and chemical properties. Research in the understanding of the nature and role of these
10

intermolecular interactions in the context of crystal packing stealthily increased with the
advancement of X-ray crystallography, giving rise to a new scientific genre, crystal
engineering.

1.5

Crystal Engineering

“Crystallization of organic ions with metal-containing complex ions of suitable sizes,
charges and solubilities results in structures with cells and symmetries determined chiefly
by packing of complex ions. These cells and symmetries are to a good extent
controllable: hence crystals with advantageous properties can be ‘engineered’…”
Pepinsky, 1955

Crystal engineering, synonymous to solid state supramolecular synthesis, focuses
on the synthesis and design of functional crystalline materials. It stems from the premise
that the crystal, described as the perfect supermolecule,34 supermolecule par excellence, 35
is the de facto manifestation of self-assembly of molecules.

Although the term was

coined in 1955 by Pepinsky, 36 it is the pioneering work by Gerald Schmidt in 1971 that is
generally considered to be the birth of crystal engineering.

37

Schmidt studied

photodimerization reactions of olefins in the solid state and determined that the
photoreactivity was governed by the stereochemical vicinity between olefins rather than
intrinsic electronic properties. He postulated that photochemical reactions occurred only
if the distance between the C=C double bonds of adjacent molecules was between 3.5 and
11

4.2 Å and the stereochemistry at the nearest neighbor double bonds were either
antiparallel (related by a crystallographic center of symmetry) or parallel (related by a
translation axis). Schmidt’s work revealed that the physical and chemical properties of
crystalline solids were dependent on the packing of the molecules within the crystal
lattice. Soon after, the focus shifted from the engineering of structures to the engineering
of properties and in 1989, Desiraju defined crystal engineering as, “the understanding of
intermolecular interactions in the context of crystal packing and the utilization of such
understanding in the design of new solids with desired physical and chemical
properties.”38

Subsequently, the field has matured into an interdisciplinary scientific

discipline with a wide scope of applications in areas such as catalysis,39 energy storage,40
electronics41 and pharmaceutics.42

1.6

Graph Set Analysis and Supramolecular Synthon
Seminal works by Etter and Desiraju were pivotal in understanding the nature of

intermolecular interaction in molecular crystals. Etter used mathematical graph theory to
delineate the nature of hydrogen bonding patterns and classify them into simpler
notations known as graph set analysis. Graph set analysis is written in the format, Gad (n)
where G is the hydrogen bond motif and can be denoted as one of the following: (1) D:
dimer or finite (2) C: chain (3) S: intramolecular (4) R: ring. The number of acceptors,
donors and atoms are denoted a, d and n respectively. Through extensive studies of
hydrogen bonding patters of organic crystals, she devised empirical rules to define the
hierarchical nature of hydrogen bonds: (1) all good proton donors and acceptors are used
(2) six membered ring intramolecular hydrogen bonds will form in preference to
12

intermolecular hydrogen bonds and (3) the best proton donors and acceptors remaining
after intramolecular hydrogen bonding will form intermolecular hydrogen bonds with
each other.43 Desiraju coined the term “supramolecular synthon” and it is defined as,
“structural units within supermolecules which can be formed and/or assembled by known
or conceivable intermolecular interactions.44 The concept was extended by Zaworotko
into

two

distinct

heterosynthons.

45

classes:

supramolecular

homosynthons

and

supramolecular

Supramolecular homosynthon is the result of intermolecular

interactions between identical self-complementary functional groups such as carboxylic
acid dimers and amide dimers (Figure 1.6), whereas supramolecular heterosynthon are
intermolecular interactions between two or more different but complementary functional
groups such as carboxylic acid-amide and carboxylic acid-aromatic nitrogen (Figure 1.7).
The concepts of graph set analysis and supramolecular synthons and the systematic
analysis of existing crystal structures is essential in crystal engineering and can be used as
a prototypal tool in the design of crystalline solids.

This is facilitated through the

technique of database mining using the Cambridge Structure Database.46

1.7

Cambridge Structural Database
The Cambridge Structural Database (CSD) is an established primary repository

for the experimentally determined 3D structures of organic and organometallic
compounds.

It is a structural visualization and analysis software developed by the

Cambridge Crystallographic Data Centre (CCDC). The CCDC was founded by the
University of Cambridge in 1965 with the primary objective:

“advancement and

promotion of the science of chemistry and crystallography for the public benefit.” The
13

CSD comprises of over half a million structures making it a comprehensive and highly
curated scientific resource for crystal engineering. The CSD facilitates reliable and fast
retrieval, visualization and analysis of experimentally measured crystallographic data to
further understand the behavior of molecules and intermolecular forces within a crystal.
This knowledge is fundamental to crystal engineering as it gives information concerning
the type of intermolecular interaction, the geometrical preferences, the directional
characteristics and the types of supramolecular synthons involved.

(a)

(b)

Figure 1.6: Illustration of (a) carboxylic acid supramolecular homosynthon and (b)
amide supramolecular homosynthon.
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Figure 1.7: Illustration of (a) carboxylic acid-amide supramolecular heterosynthon and
(b) carboxylic acid-aromatic nitrogen supramolecular heterosynthon.

1.8

Cocrystal

1.8.1

Definition
The definition of cocrystal is an active subject of debate. The debate started in

2003 when Desiraju expressed the unsuitability of the term co-crystal and suggested that
the previously used terms such as molecular complexes should be adhered to. 47 Dunitz,
however, stated that the term molecular complex is too vague and while the term “cocrystal” is not perfect, it has been irrevocably established.48 He defined a co-crystal as “a
crystal containing two or more components together.” Both Dunitz and Desiraju agreed
that the term should be “co-crystal” in contrast to “cocrystal” to indicate togetherness of
two components. Aakeroy offered a more restrictive definition in that the components of
cocrystals must be neutral and exists as a solid at ambient conditions with a well-defined
stoichiometry. 49

However, Bond found this definition unsatisfactory due to the

restriction that all components must be solid.50 Zaworotko proposed the definition, “a
15

stoichiometric multiple component crystal that is formed between two crystalline
materials that are solids under ambient conditions. At least one of the components is
molecular (target molecule) and forms a supramolecular synthon with the remaining
component (cocrystal former).”

1.8.2

History
The earliest example of a cocrystal was quinhydrone, a complex formed between

hydroquinone and quinone reported by Wohler in 1844.51 Subsequently, other examples
of cocrystals were reported in the literature but were called organic molecular
compounds

52

, heteromolecular crystals,

53

molecular complexes

54

and addition

compounds.55 The term ‘cocrystal’ was coined in 1967 to describe the hydrogen bonded
complex formed 9-methyladenine and 1-methylthymine (Fig. 1.8) 56 and was later
popularized through the works of Etter.57 Cocrystals are of topical interest because they
create an opportunity to address the hierarchy of intermolecular interactions and they
have applications in pharmaceutical formulation, non-linear optics and green chemistry.

Figure 1.8: Interaction between 9-methyladenine and 1-methylthymine molecules.
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1.8.3

Designing Cocrystals
The design of cocrystals utilizes the first principles of crystal engineering and

self-assembly of molecules.

It places emphasis on the hierarchy of supramolecular

synthons by evaluating the reliability of intermolecular interactions between specific
functional groups and analysis of the crystal packing. Design strategies, such as the
supramolecular synthon approach comprises of examining the arrangement and
frequency of occurrence of supramolecular synthons formed between functional groups.
The supramolecular synthon approach consists of the following steps: (1) identifying the
functional groups present on the target molecule (2) perform an empirical analysis of the
supramolecular heterosynthons formed between complementary functional groups of
experimental crystal structures using the CSD and (3) arrange in hierarchical order the
robust or commonly occurring supramolecular synthons and select the cocrystal formers
accordingly. This method is advantageous in delineating the hierarchy of supramolecular
synthons between complementary functional groups. 58 Bis et al studied the preferential
interaction between alcohols and aromatic nitrogen, Narom in the presence of cyano
functional groups. 59

Shattock and others focused on the ability of alcohols and

carboxylic acids to form reliable supramolecular heterosynthons in the presence of
competing functional moieties. 60 Kavuru and coworkers discussed the formation of
charge assisted H bonds between carboxylates and weakly acidic hydroxyl moieties.61

1.8.4

Cocrystal Synthesis
Mechanochemistry, grinding of solids, has been used in the preparation of

cocrystals since the 19th century. Also known as neat grinding or dry grinding, 62,63 it is a
17

cost effective and environmentally-friendly technique and provides a cleaner alternative
to conventional solution based approaches. Some of the early examples of cocrystals
were produced by grinding which include the preparation of the quinhydrone cocrystal,23
charge transfer complexes64 and methyladenine and methylthymine cocrystal.65 Shan and
coworkers demonstrated a modified mechanochemistry technique known as solvent drop
grinding (liquid assisted grinding) where the addition of minute amount of solvent
increased kinetics of cocrystal formation.66 Alternative methods for the preparation of
cocrystals include melt crystallization, solution based methods such as slow evaporation,
slurrying and SonicSlurry, 67 supercritical fluid crystallization, 68 twin screw extrusion69
and spray drying. 70 Systematic studies have been implemented to understand the
thermodynamic factors in the formation of cocrystals.

Nair pioneered reaction

crystallization, where the formation of the cocrystal is driven by the non-stoichiometric
concentration of the individual components.71

She suggested that the solubility of the

cocrystal can be represented as the product of the component concentrations.
Ksp = [A]a [B]b

(1)

Where [A] and [B] are molar concentrations of individual components at equilibrium
Therefore, an increase in the concentration of the more soluble component in excess of
their stoichiometric composition will lower the solubility of the stable cocrystal and
hence it will crystallize out of solution. Chiarella and coworkers used ternary phase
diagrams to deduce that cocrystal formation takes place in the region of the phase
diagram where the cocrystal is the stable solid phase.72 They rationalized that screening
of new cocrystal of a particular system should be determined by the relative solubilities
of the two components rather than stoichiometry.
18

ter Horst and coworkers determined

that cocrystal formation can be assessed by comparing the saturation temperature
corresponding to where both components are saturated and the saturation temperature of
the pure components. 73 Given that the saturation temperature of both components is
higher than the saturation temperature of pure components indicates that a stable, less
soluble cocrystal phase has been formed.

Zhang et al reported a suspension/slurry

technique known as solution mediated phase transformation.74 This method is based on
the principle that when crystals of both single components are present in excess, the
cocrystal forms spontaneously.

1.9

Impact of Pharmaceutical Cocrystals

1.9.1

Solubility
One of the earliest examples of the solubility of a drug complex, digoxin-

hydroquinone was reported by Higuchi and Ikeda in 1974.75 Although it was not termed
a cocrystal, the authors showed the improvement of solubility of the complex in
comparison to the free drug digoxin. However, itraconazole is considered to be the first
example of an API that addressed the use of pharmaceutical cocrystals to modify
physicochemical properties of APIs. Almarrson et al reported the dissolution studies of
the antifungal drug itraconazole with 1,4-dicarboxylic acids. All the cocrystals revealed
an enhanced dissolution of 4-20 fold higher than the itraconazole free base and the
dissolution rate of itraconazole-malic acid was comparative to the marketed amorphous
form (Fig. 1.9). 76 In 2004, Childs and others demonstrated the use of pharmaceutical
cocrystals to significantly modify the physicochemical properties of the API, fluoxetine
19

HCl. 77 Fluoxetine HCl was cocrystallized with benzoic acid, succinic acid and fumaric
acid.

The dissolution profiles of the cocrystals revealed that they had an aqueous

solubility that was 50% less (benzoic acid), comparable (fumaric acid) or 2 fold higher
(succinic acid) than the crystalline salt of the API (Fig. 1.10). An intriguing observation
in the dissolution profile of the pharmaceutical cocrystal of fluoxetine HCl and succinic
acid was its “spring and parachute.” The “spring” illustrates a high energy form of the
API which enables it to solubilize rapidly and the “parachute” is the transition from high
energy forms to more stable crystal energy forms.78 Since 2003, the ability to increase
the solubility of APIs via pharmaceutical cocrystals has been reiterated through several
studies.

Fig. 1.9: Dissolution profile of pharmaceutical cocrystals of itraconazole.
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1.9.2

Bioavailability
Seminal studies by Hickey and McNamara demonstrated that pharmaceutical

cocrystals are a viable method to alter the pharmacokinetic profile of a drug. Hickey and
coworkers reported higher exposure levels in dogs of the pharmaceutical cocrystal
carbamazepine-saccharin in comparison to the marketed anhydrous form.79 McNamara
et al performed bioavailability studies in dogs on a 1:1 pharmaceutical cocrystal
composing of a sodium channel blocker API and glutaric acid. The cocrystal exhibited a
3-fold increase in the plasma concentration in dose levels of 5 and 50mg/kg. In addition,
the cocrystal exhibited an increase in the intrinsic dissolution rate of 18 times in contrast
to the pure drug.

80

About the same time, In another study, L-883555, a

phosphodiesterase IV inhibitor was cocrystallized with l-tartaric acid, and the cocrystal
exhibited an area under the concentration– time curve (AUC) of 5.5 as compared to 0.24
exhibited by the free base. 81 Bak et al described the pharmacokinetics of AMG517sorbic acid cocrystal in Sprague-Dawley rats and at 500 mg/kg dose, the peak plasma
concentration of AMG517 in the cocrystal was 7 times higher than the free base. 82
Further pharmacokinetic studies of AMG517 with a series of carboxylic acids and amides
showed improvement. 83 , 84 Investigation in the dissolution and bioavailability of
lamotrigine revealed that the anlydrate and monohydrated cocrystal of lamotriginenicotinamide had lower serum concentration than the pure drug although the powder
dissolution rates were higher.85
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Fig. 1.10: Dissolution profile of pharmaceutical cocrystals of fluoxetine HCl.

1.9.3

Hydration Stability
Hydration stability is relevant in pharmaceutical science because the

transformation of one crystal form to another jeopardizes the desired physicochemical
properties of the API. A prominent example is illustrated by stability studies of six
pharmaceutical cocrystals of caffeine. Caffeine, a central nervous system stimulant,
converts to its hydrated form between relative humidity 75 and 98%. The study revealed
that the 2:1 pharmaceutical cocrystal caffeine-oxalic acid was very stable upon exposure
of 98% relative humidity over seven weeks. 86 Similar studies were done on four
pharmaceutical cocrystals of theophylline with oxalic acid, glutaric acid, malonic acid
and maleic acid. It was shown that only the pharmaceutical cocrystal theophylline-oxalic
acid displayed an improvement in the physical stability, the remaining cocrystals had
similar stability to theophylline. 87

Other studies demonstrate that carbamazepine-

saccharin cocrystal was physically stable at 60% relative humidity and 75% relative
22

humidity for two weeks, despite the fact that carbamazepine readily forms the dihydrate
under these conditions.73

1.9.4

Mechanical properties
Pharmaceutical cocrystals can be used to alter the mechanical properties of APIs

as exemplified by studies involving caffeine-methylgallate cocrystal. The cocrystals
showed high tensile strength and improved tableting properties in comparison to the
individual components.88 The improvement in mechanical properties was presumed to be
attributed to the layered structure of the cocrystal. Another example is illustrated in the
study of tablet formation and mechanical properties on pharmaceutical cocrystals of
paracetamol, form I with naphthalene, theophylline, oxalic acid and acridine.89 Threelayered crystal structures of paracetamol were constructed using only planar cocrystal
formers and as a result the weak shear planes promoted improved elasticity and
tabletability.

1.10

Overview of Dissertation
Pharmaceutical cocrystals have matured to be an integral part of pharmaceutical

solid form development because they afford the discovery of novel, diverse crystal forms
of APIs and therefore generate new intellectual property. In addition, pharmaceutical
cocrystals have been demonstrated to be a viable approach to profoundly modify the
physicochemical

properties

such

as

solubility/dissolution

rate,

stability

and

bioavailability.

Consequently, several factors regarding their development and

application becomes of interest which includes but not limited to: the selection of
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potential cocrystal formers, development of cocrystals screening methods, scale-up
techniques, optimal design, characterization and evaluation of the physicochemical
properties of cocrystals in comparison to the target molecule. This dissertation seeks to
understand design strategies in the supramolecular synthesis of cocrystals and address the
opportunities and challenges that exist in crystal engineering.
Chapter 2 demonstrates the use of nutraceuticals as cocrystal formers. Typically,
cocrystal formers are limited to pharmaceutically approved carboxylic acids and chemical
included in the generally regarded as safe (GRAS)90 and everything added to food in the
United States (EAFUS) lists.91 However, the library of cocrystal formers can be expanded
to include other classes of compounds that have an acceptable toxicity profile such as
nutraceuticals. The nutraceuticals, gallic acid and ferulic acid were selected since they
possess phenolic and carboxylic acid moieties that are capable of forming reliable
supramolecular synthons with complementary functional moieties. The cocrystals were
systematically designed by applying the supramolecular synthon approach.
Chapter 3 reveals a crystal engineering design strategy in the synthesis of
isostructural pharmaceutical cocrystals of the anti-psychotic API olanzapine.

This

strategy involved a comprehensive analysis of the crystal packing and hydrogen bonding
patterns of known crystal structures of olanzapine.

This analysis was utilized to

synthesize isostructural quaternary multi-component crystal forms of olanzapine. These
crystal forms consist of olanzapine, the cocrystal former, a water molecule and a solvate.
This strategy is particularly effective in the systematic and successful design of
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pharmaceutical cocrystals of complex APIs that possess multiple functional groups
and/or conformational flexibility.
Chapter 4 (Appendix 2) addresses the role of water molecules in crystal
engineering by studying the relationship between crystal structures and thermal stabilities
of a series of synthesized cocrystal hydrates. It was found that their stoichiometric
compositions, crystal packing are unpredictable. In addition, there was no correlation
found between the crystal packing and thermal stability even when composition and
structure are similar. Database mining using the CSD of crystalline hydrates possessing
the functional groups carboxylic acids and phenols revealed the unpredictability of
supramolecular synthons exhibited by hydrates due to the versatility of the water
molecule to engage in diverse hydrogen bonding interactions.
Chapter 5 (Appendix 3) reports forms III and IV polymorphic forms of gallic acid
monohydrate. This is the first tetramorphic hydrate for which fractional coordinates have
been determined. An analysis of the hydrogen bonding patterns in these and other
polymorphic hydrates suggests that waters of hydration are in general a nemesis to crystal
engineers.
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Chapter 2: A Crystal Engineering Study of Gallic Acid and Ferulic Acid as
Cocrystal Formers

2.1

Introduction
Crystal engineering 1 , the design of new molecular solids through invoking

supramolecular chemistry, continues to invoke interest through the rapidly emerging
fields of metal organic frameworks

2

, solid-state synthesis

3

and pharmaceutical

cocrystals.4
The definition of a cocrystal is an active subject of discussion;5 we define it as “a
stoichiometric multiple component crystal that is formed between two compounds that
are solids under ambient conditions in which at least one cocrystal former is molecular
and forms a supramolecular synthon with the remaining cocrystal former(s).” Cocrystals6
represent a long known but little studied class of compounds as they have been known
since the 1840’s7 but even today they represent less than 0.5% of the structures that have
been archived in the Cambridge Structural Database (CSD).8 Pharmaceutical cocrystals,
cocrystals

formed

between

active

pharmaceutical

ingredients

(APIs)

and

a

pharmaceutically acceptable cocrystal former have emerged into a new paradigm in
pharmaceutical science as they afford new crystal forms of APIs without covalently
modifying the API and they also create opportunities for intellectual property. 9 Most
importantly, they modify the physicochemical properties of the API such as stability, 10
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mechanical properties11 and solubility.12 As pharmaceutical cocrystals have become an
inherent part of pharmaceutical solid form development, the selection of cocrystal former
libraries remains a matter of debate.

Conventional wisdom suggests that

pharmaceutically approved carboxylic acids and chemicals included in the generally
regarded as safe (GRAS)13 and everything added to food in the United States (EAFUS)
lists14 are, in effect, the cocrystal former library. However, there are many other “safe”
cocrystal formers that have the potential to serve as cocrystals formers as exemplified by
nutraceuticals.15
Nutraceuticals are naturally occurring compounds defined as “food, or parts of
food, that provide medical or health benefits, including the prevention and/or treatment of
diseases.”

16

They include dietary supplements, isolated natural substances and

genetically-engineered designer foods, and are differentiated from pharmaceuticals by the
claims, dosage and packaging of the product. 17 Most nutraceuticals are derived from
plants and exist as amino acids, carotenoids, vitamins and dietary polyphenols. Dietary
polyphenols, secondary plant metabolites, represent a wide variety of compounds that
occur in fruits, vegetables, wine, tea, and cocoa products. They are mostly derivatives
and/or isomers of flavonoids, stilbenes, catechins, and phenolic acids. They exhibit many
biologically significant functions, such as protection against oxidative stress and
degenerative diseases, due to their antioxidant properties. 18 Phenolic acids present in
plants are hydroxylated derivatives of benzoic and cinnamic acids such as gallic acid and
ferulic acid.19 They account for one third of the total intake of dietary polyphenols in the
diet. Ferulic acid, a hydroxycinnamic acid, is concentrated in the bran of grains, peel of
fruits and roots and peels of vegetables.20 It is a bioactive agent that is found as the free
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form or the conjugate form and has been approved as an additive antioxidant and food
preservative in Japan.21 Gallic acid is found in the free form or esterified to catechins or
proanthocyanidins.

It is widely used as antioxidant in the pharmaceutical industry

because in vivo and in vitro studies have shown that it is cytotoxic against cancer cells, 22
possesses antibacterial and antifungal properties23 and has been found to be active against
the viruses HIV-1 and HSV-1.24
Phenolic acids are strong candidates to serve as cocrystal formers, because they
possess multiple hydrogen bond donors and acceptors that are capable of forming a stable
and diverse range of supramolecular synthons.

Furthermore, carboxylic acids and

phenols are frequently encountered in APIs, pharmaceutical excipients and salt formers
and can act as both hydrogen bond donors and hydrogen bond acceptors. They are
therefore self-complementary and can also engage in robust and reliable supramolecular
heterosynthons with complementary functional groups as seen in the examples of
supramolecular synthons composed of carboxylic acid dimers, 25 amide dimers, 26
carboxylic acid-basic nitrogen, 27 carboxylic acid-amides, 28 phenol-basic nitrogen 29 and
phenol-carboxylates.30 An effective approach in the design of cocrystals is applying the
supramolecular synthon approach, in particular exploiting reliable supramolecular
synthons.

This approach involves an empirical analysis of the arrangement and

frequency of occurrence of supramolecular synthons of a large number of crystal
structures using the Cambridge Structural Database (CSD).8

A high probability of

occurrence of a particular supramolecular synthon suggests a robust and reliable
supramolecular synthon.
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This paper addresses the use of gallic acid and ferulic acid, both of which are
phenolic acids as cocrystal formers. Eleven cocrystals of gallic acid and ferulic acid with
cocrystal formers (Figure 2.1): isoniazid (INZ), adenine (ADN), 3,5-dimethylpyrazole
(DMP), theobromine (TBR), urea (URE) and glycine anhydride (GAH) were isolated
and structurally characterized.
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Figure 2.1. Cocrystal formers used herein, abbreviated as follows: INZ, ADN, DMP,
TBR, URE, GAH.

2.2

Materials and Methods

2.2.1

Materials

All reagents and solvents were purchased from commercial vendors and used without
further purification.
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2.2.2

Preparation of Cocrystals

Gallic Acid.Isoniazid, GALINZ: Gallic acid (17.0 mg, 0.100 mmol) and iso-nicotinic
acid hydrazide (13.8 mg, 0.100 mmol) were dissolved in 2ml of methanol until a clear
solution was obtained. The solution was left for slow evaporation at room temperature.
Light brown prisms of GALINZ were obtained after 5 days.
Gallic Acid.Dimethypyrazole, GALDMP: Gallic acid (59.2 mg, 0.348 mmol) and 3,5dimethylpyrazole (35.4 mg, 0.368 mmol) were dissolved in 5ml of methanol until a clear
solution was obtained. The solution was left for slow evaporation at 5oC. Colorless
prisms of GALDMP were obtained after 14 days.
Gallic Acid.Adenine, GALADN: Gallic acid (17.0 mg, 0.100 mmol) and adenine (13.7
mg, 0.100 mmol) were dissolved in a 4 ml water/ethanol (1:3 ratio) and allowed to slowly
evaporate at room temperature in a fume hood. Colorless needles of GALADN were
harvested after 3 days.
Gallic Acid.Urea, GALURE:

Gallic acid (17.1 mg, 0.100 mmol) was dissolved in 1

ml of ethanol. The solution was added to 1 ml saturated solution of urea and allowed to
slowly evaporate at room temperature in a fume hood. Colorless needles of GALURE
were harvested after 8 days.
Gallic Acid.Glycine Anhydride, GALGAH: Gallic acid (17.0 mg, 0.100 mmol) and
glycine anhydride (12.0 mg, 0.105 mmol) were dissolved in 2ml of 50% aqueous acetone
solution. The solution was left for slow evaporation at 5oC.
GALGAH were obtained after a 7 days.
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Colorless needles of

Ferulic Acid.Adenine, FERADN: Ferulic Acid (19.4 mg, 0.100 mmol) and adenine
(13.7 mg, 0.100 mmol) were dissolved in a 4 ml water/ethanol (1:3 ratio) and allowed to
slowly evaporate at room temperature in a fume hood. Colorless needles of FERADN
were obtained after 9 days.
Ferulic Acid.Isoniazid, FERINZ:

Ferulic acid (19.0 mg, 0.100 mmol) and

isoniazid (13.7 mg, 0.100 mmol) were dissolved in 2ml of ethanol. The solution was left
for slow evaporation at 5oC. Colorless needles of FERINZ were obtained after a 3 days.
Ferulic Acid.Dimethypyrazole, FERDMP: Ferulic acid (19.4 mg, 0.100 mmol) and
3,5-dimethylpyrazole 9.6 mg, 0.100 mmol) were dissolved in 5ml of methanol until a
clear solution was obtained. The solution was left for slow evaporation at 5oC. Yellow
plates of FERDMP were obtained after 14 days.
Ferulic Acid.Urea, FERURE: Ferulic acid (19.2 mg, 0.100 mmol) was dissolved in 2
ml of ethanol. The solution was added to 1 ml saturated solution of urea and allowed to
slowly evaporate at room temperature in a fume hood. Colorless needles of FERURE
were harvested after 8 days.
Ferulic Acid.Glycine Anhydride, FERGAH: Ferulic acid (19.0 mg, 0.1 mmol) and
glycine anhydride (79.0 mg, 0.693 mmol) were dissolved in 2ml of 50% aqueous acetone
solution. The solution was left for slow evaporation at 5oC.

Colorless needles of

FERGAH were obtained after a 10 days.
Ferulic Acid.Theobromine, FERTBR:

Ferulic acid (19.0 mg, 0.100 mmol) and

theobromine (19.0 mg, 0.693 mmol) were dissolved in 4ml of 50% aqueous ethanol
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solution. The solution was left for slow evaporation at room temperature. Colorless
needles of FERTBR were obtained after a 14 days.
2.2.3

Methods

Differential scanning calorimetry (DSC): Thermal analysis of the cocrystals was
performed using a TA instrument DSC 2920 Differential Scanning Calorimeter.
Hermetic aluminum pans were used for all samples and temperature calibrations were
made using indium as a standard. The samples (1-3 mg) were scanned at a heating rate of
10 °C/min from 30oC-350oC under a dry nitrogen atmosphere (flow rate 70ml/min).
Thermogravimetric analysis (TGA): Thermogravimetric analysis was performed with a
Perkin Elmer STA 6000 Simultaneous Thermal Analyzer. Open alumina crucibles were
used for analysis in the temperature range 30°C to the appropriate temperature at 2-10
°C/min scanning rate under nitrogen stream.
Infrared spectroscopy (FT-IR): All crystalline samples were characterized by infrared
spectroscopy using a Nicolet Avatar 320 FT-IR instrument. 2-3mg of material was used
for all samples. Spectra were measured over the range of 4000 – 400cm-1 and data were
analyzed using EZ Omnic software.
Laboratory powder x-ray diffraction (PXRD): Bulk samples were analyzed by x-ray
powder diffraction with a Bruker AXS D8 powder diffractometer using Cu Kα radiation
(λ = 1.54056 Ǻ) and 40 kV; 30 mA. Scanning interval of data was in the range of 3–40°
2θ; time per step 0.5s. The experimental PXRD patterns and calculated PXRD patterns
from single crystal structures were compared to confirm the composition of materials.
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Single-crystal x-ray data collection and structure determinations: Suitable single
crystals of GALURE, GALGAH, GALINZ, GALDMP, FERADN, FERURE,
FERGAH and FERINZ were selected for single crystal x-ray crystallography. Quality
single crystals of FERDMP and GALADN could not be obtained but the crystal
structure of GALADN was solved from the synchrotron powder X-ray diffraction pattern
as described below. The validity of structure solution of cocrystals from powder x-ray
diffraction pattern has been well established, although structures from powder data
generally have less precision in atomic positions than those from single crystal data. 31
The diffraction data for single crystals of GALDMP was collected on a Bruker-AXS
SMART APEX CCD diffractometer with monochromatized Mo Kα radiation ((λ =
0.71073 Å), whereas data for single crystals of the hydrates of GALURE, GALGAH,
GALINZ, FERADN, FERURE, FERGAH and FERINZ were collected on a BrukerAXS SMART APEX 2 CCD diffractometer with monochromatized Cu Kα radiation (λ =
1.54178 Å). Diffractometers were equipped with KRYO-FLEX low temperature device
and diffraction experiments were carried out at 100K. Indexing was performed using
SMART v5.625 32 or using APEX 2008v1-0. 33 Frames were integrated with SaintPlus
7.5134 software package. Structures were solved by direct methods and refined by full
matrix least-squares based on F2 using the SHELXTL package.35 Absorption correction
was performed by a multiscan method implemented in SADABS.36 All non-hydrogen
atoms were refined anisotropically. Hydrogen bonds were solved as follows:
GALINZ: Hydrogen atoms of NH2 groups were located from difference Fourier map and
freely

refined

except

H7

for

which

Uiso(H)

=

1.2Ueq(-NH).

All the other hydrogen atoms were placed geometrically and refined using riding model
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with isotropic thermal parameters Uiso(H) = 1.5Ueq(-OH,-CH3), Uiso(H) = 1.2Ueq(CH,-NH).
GALDMP: Hydrogen atoms of -OH and =NH groups were located from the difference
Fourier map and refined freely or freely with thermal parameters: Uiso(H) = 1.5Ueq(OH) for H231 and H271. Hydrogen H271 was refined using distance restraints (free
refinement resulted in 1.055A O-H distance). All the other hydrogen atoms were placed
geometrically and refined using riding model with isotropic thermal parameters Uiso(H)
= 1.2Ueq(-CH), Uiso(H) = 1.5Ueq(-CH3).
GALURE: Hydrogen atoms of NH2 groups were located from difference Fourier map
and freely refined with isotropic thermal parameters. All the other hydrogen atoms were
placed geometrically and refined using riding model with isotropic thermal parameters
Uiso(H) = 1.5Ueq(-OH), Uiso(H) = 1.2Ueq(-CH).
GALGAH: Hydrogen atoms of NH groups were located from difference Fourier map
and freely refined with isotropic thermal parameters. All the other hydrogen atoms were
placed geometrically and refined using riding model with isotropic thermal parameters
Uiso(H) = 1.5Ueq(-OH), Uiso(H) = 1.2Ueq(-CH2,-CH).
FERADN: Hydrogen atoms of NH2 group were located from difference Fourier map and
refined using distance restraints with isotropic thermal parameters (Uiso(H) = 1.5Ueq(NH2).
All the other hydrogen atoms were placed geometrically and refined using riding model
with isotropic thermal parameters Uiso(H) = 1.5Ueq(-OH,-CH3), Uiso(H) = 1.2Ueq(CH,-NH).
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FERINZ: Hydrogen atoms of NH2 group were located from difference Fourier map and
refined using distance restraints with isotropic thermal parameters (Uiso(H) = 1.5Ueq(NH2). All the other hydrogen atoms were placed geometrically and refined using riding
model with isotropic thermal parameters Uiso(H) = 1.5Ueq(-OH,-CH3), Uiso(H) =
1.2Ueq(-CH,-NH).
FERURE: Hydrogen atoms of -OH groups were located from the difference Fourier map
and freely refined. All the other hydrogen atoms were placed geometrically and refined
using riding model with isotropic thermal parameters Uiso(H) = 1.2Ueq(-CH,-CH2,-NH),
Uiso(H) = 1.5Ueq(-CH3, -OH).
FERGAH: All hydrogen atoms were placed geometrically and refined using riding
model with isotropic thermal parameters Uiso(H) = 1.2Ueq(-CH,-NH2), Uiso(H) =
1.5Ueq(-CH3,-OH).
Crystallographic data are presented in Table 2.1. Hydrogen bond parameters are given in
Table 2.2.
Synchrotron powder x-ray data collection and structure determinations: A high
resolution synchrotron X-ray powder diffraction pattern was collected at the X16C
beamline at the National Synchrotron Light Source at Brookhaven National Laboratory.
X-rays of wavelength 0.700154 Å were selected using a Si(111) channel cut
monochromator. After the sample, the diffracted beam was analyzed with a Ge(111)
crystal and detected by a NaI scintillation counter. Wavelength and diffractometer zero
were calibrated using a sample of NIST Standard Reference Material 1976, a sintered
plate of Al2O3. Samples were flame-sealed in thin walled glass capillaries of nominal
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diameter 1.5 mm and spun during data collection for improved powder averaging. This
measurement was performed at ambient temperature, nominally 295 K.

Figure 2.2: High-resolution synchrotron powder diffraction data (dots) and Rietveld fit
of the data for GALADN. The lower trace is the difference, measured minus calculated,
plotted to the same vertical scale
TOPAS-Academic37,38,39 was used to index, solve, and refine the crystal structure
of GALADN. From systematic absences in the pattern, a space group of P21/c was
hypothesized.

Structure solution was performed by simulated annealing, with each

molecule being defined as a rigid body on a general position. From this preliminary
solution, Rietveld refinement was successfully performed (Figure 2.2). Both of the
molecules were defined as rigid bodies, with similar bonds and angles (aromatic bonds,
C-C single bonds, e.g.) refined jointly to a single value. The powder diffraction data set
does not contain sufficient information to give reliable hydrogen atom positions.
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GALINZ
Formula

C13H13N3O
6

GALDMP

GALADN

GALURE

GALGAH

C17H22N4O5

C12H11N5O5

C8H10N2O6

C11H12N2O7

MW

307.26

362.39

305.25

230.18

284.23

Crystal
system

Triclinic

Triclinic

Monoclinic

Monoclinic

Triclinic

Space group

P-1

P-1

P21/c

P21/c

P-1

a (Å)

8.6337(3)

8.074(2)

7.96634(14)

9.7502(3)

6.0418(2)

b (Å)

11.9056(5)

8.149(2)

6.33221(23)

9.8774(3)

7.9997(2)

c (Å)
α (deg)
β (deg)
γ (deg)
V / A3
Dc/g cm-3
Z

13.3621(5)
94.353(2)
99.401(2)
108.929(2)
1269.47(8)
1.608
4
3.38 to
65.97

15.091(4)
95.811(5)
93.004(5)
117.408(4)
871.4(4)
1.381
2

24.8483(4)
90
96.2093(16)
90
1246.11(4)
1.589
4

10.2927(3)
90
109.204(2)
90
936.09(5)
1.633
4

13.0244(3)
103.309(2)
91.082(2)
109.7880(10)
573.19(3)
1.647
2

2.73 to 25.03

3 to 40

4.80 to 67.95

3.51 to 66.04

2θ range
Nref./Npara

4165/420

3031/265

-

1677/166

1914/196

T /K

100(2)

100(2)

300

100(2)

100(2)

R1 [I>2σ (I)]

0.0444

0.0406

-

0.0323

0.0369

wR2
Rwpa
Rexpb
GOF
Abs coef

0.1130
0.999
1.109

0.1060
1.039
0.103

0.0725
0.0476
1.523
0.123

0.0853
1.084
1.237

0.0925
1.095
1.211

FERINZ

FERADN

FERURE

FERGAH

FERTBR

C15H15N5O4

C14H18N4O6

C14H16N2O6

C17H20N4O7

331.33

329.32

314.30

308.29

392.37

Monoclinic

Orthorhombic

Monoclinic

Monoclinic

Monoclinic

P21/c

Pca21

P21/c

Pc

C2/c

13.681(4)

13.2739(4)

19.950(1)

10.9682(3)

30.546(4)

Formula

C16H17N3O
5

MW
Crystal
system
Space group
a (Å)
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b (Å)

3.798(12)

16.2621(5)

10.2970(5)

12.7359(3)

6.8895(9)

c (Å)
α (deg)
β (deg)
γ (deg)
V / A3
Dc/g cm-3
Z

29.843(10)
90
101.914(5)
90
1517(5)
1.451
4
3.30 to
44.48

6.9427(3)
90
90
90
1498.66(9)
1.460
4

7.2349(4)
90
94.914(3)
90
1480.77(13)
1.410
4
2.22 to
65.82

10.2315(3)
90
97.599(2)
90
1416.69(7)
1.445
4

17.209(2)
90
93.725(6)
90
3619.9(8)
1.442
8

3.47 to 65.98

2.90 to 52.63

2θ range
Nref./Npara

2.72 to 67.07

1206/229

2421/226

2497/208

4124/403

2042/259

T /K

293(2)

100(2)

100(2)

225(2)

298(2)

R1 [I>2σ (I)]

0.0762

0.0354

0.0445

0.0537

0.0742

wR2
Rwpa
Rexpb
GOF
Abs coef

0.1734
0.994
0.920

0.0827
1.065
0.918

0.1062
1.081
0.974

0.1413
1.004
0.971

0.1965
1.016
0.965

Table 2.1: Crystallographic data and structure refinement parameters for the cocrystals
presented herein.
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where yicalc and yiobs are the calculated and observed intensities at the ith point in the
profile, normalized to monitor intensity. The weight wi is 1/2 from the counting
statistics, with the same normalization factor. N is the number of points in the measured
profile minus number of parameters.
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Hydrogen bond
GALINZ

GALDMP

GALURE

GALGAH

FERINZ

N-HO
N-HO
N-HO
N-HO
O-HO
O-HO
O-HN
O-HN
O-HN
O-HN
N-HO
N-HO
O-HN
O-HN
O-HO
O-HO
O-HO
O-HN
O-HO
O-HO
O-HO
O-HO
N-HO
N-HO
N-HO
N-HO
O-HO
O-HO
O-HO
O-HO
N-HO
N-HO
O-HO
O-HO
O-HN
N-HO
N-HO
N-HO

d (H · · · A)
/Å
2.20
2.56(3)
2.24
2.18(3)
2.07
2.04
1.80
1.89
1.84
1.87
2.14(2)
1.95(2)
1.67(3)
2.51(2)
1.97(2)
2.27(2)
1.84(3)
1.658(18)
1.73
1.89
2.04
2.10
2.37(2)
2.542(19)
2.31(2)
2.12(2)
1.80
2.06
1.91
1.78
1.94(2)
2.08(2)
2.19
2.37
1.82
2.06(2)
2.32(4)
2.25(7)
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D (D · · · A)/Å <(DHA)
2.942(2)
3.427(3)
2.913(2)
3.044(3)
2.802(2)
2.755(2)
2.636(2)
2.717(2)
2.675(2)
2.699(2)
2.9314(19)
2.8092(19)
2.6190(18)
3.3135(19)
2.7410(16)
2.7283(16)
2.6800(17)
2.5891(17)
2.5282(14)
2.7012(14)
2.8346(14)
2.8263(14)
3.2347(17)
3.0048(17)
2.8264(17)
2.9961(18)
2.6382(14)
2.7229(15)
2.7480(15)
2.6102(15)
2.8537(17)
2.9349(17)
2.647(8)
3.000(8)
2.634(9)
2.91(1)
3.17(1)
2.96(1)

142.2
169(2)
132.8
162(2)
145.3
142.8
174.8
167.6
173.9
167.6
151.7(17)
162(2)
167(2)
140.6(18)
144.9(19)
112.0(17)
160(2)
169(3)
158.5
162.4
156.5
144.7
159.9(16)
112.2(15)
120.0(16)
168.5(18)
178.6
135.2
175.7
169.1
165.7(18)
166.7(19)
115.8
134.4
174.6
176(8)
159(8)
137(8)

FERADN

FERURE

FERGAH

FERTBR.H2O

O-HN
N-HN
N-HO
O-HO
N-HO
N-HO
N-HO
N-HO
N-HO
N-HO
N-HO
N-HO
O-HO
O-HO
O-HO
N-HO
N-HO
O-HO
O-HO
N-HO
O-H(W)O
O-H(W)O

1.98
2.00
2.09(2)
1.75(3)
2.14
2.32
2.41
2.08
2.25
2.06
2.07
2.29
1.72(4)
2.02
2.01
2.58
2.25
1.79
1.89
2.00
2.09(5)
1.90(3)

2.715(2)
2.826(2)
2.964(3)
2.639(2)
2.983(3)
3.023(2)
3.108(2)
2.951(3)
2.986(2)
2.936(2)
2.945(2)
3.079(2)
2.616(2)
2.677(5)
2.646(4)
3.157(5)
3.097(5)
2.600(7)
2.710(7)
2.858(7)
2.865(7)
2.764(7)

146
155
164(2)
168(3)
160.7
136.4
137.0
168.5
141.2
172.1
174.2
150.0
135.1
132.5
124.5
164.1
167.4
175.5
172.5
150(7)
169(9)

Table 2.2: Selected hydrogen bond distances and parameters of cocrystals

Supramolecular Synthon

COOH…CONH
COOH…COOH
CONH…CONH

Carboxylic acids and
Primary Amides
Raw
Refined
(254
(38 entries)
entries)
124
32 (84.2%)
(48.8%)
15 (5.9%)
3 (7.9%)
87 (34.3%)
4 (10.5%)

Carboxylic acids and
Secondary amides
Raw
Refined
(1141
(184 entries)
entries)
78 (6.8%)
7 (3.8%)
123 (10.8%)
117 (10.3%)

40 (21.7%)
36 (19.6%)

Table 2.3: Comparison of Supramolecular Homosynthon versus Supramolecular
Heterosynthon of Carboxylic acids with Primary and Secondary Amides
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2.3

Results

GALINZ: GAL and INZ form a cocrystal that crystallizes in the space group P-1 with
two independent molecules of GAL and two independent molecules of INZ in the
asymmetric unit.

The crystal structure reveals the existence of hydrogen bonded

interactions between the two symmetrically independent GAL molecules via phenolic
supramolecular homosynthons (O…O: 2.757(1), O…O: 2.805 (1)Å). The phenolic
homodimers of GAL act as H-bond donors and acceptors to the hydrazide moieties of the
two symmetrically independent molecules of INZ via R33(7) ring motifs so as to form
four component supramolecular assemblies of GAL and INZ molecules.

This four

component supramolecular assembly in turn forms H-bonded tapes that are sustained by
COOH…Nbasic supramolecular heterosynthons (O…N: 2.636(3) Å), thereby forming a two
dimensional network (Fig. 2.3a). The carbonyl moiety of one symmetrically independent
GAL molecule hydrogen bonds with the amine moiety of INZ (N…O: 3.044(1) Å) to
form bilayers that are connected by π interactions (Fig. 2.3b).

(a)
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(b)
Fig 2.3: (a) Crystal packing in GALINZ reveals form H-bonded tapes that are sustained
by COOH…Nbasic supramolecular heterosynthons (b) Illustration of bilayers of GALINZ
sheets.

GALDMP: GALDMP is a 1:2 cocrystal that crystallizes in space group P-1 with one
molecule of GAL and two molecules of DMP in the asymmetric unit. The crystal
structure of GALDMP reveals that GAL molecules form phenolic supramolecular
homosynthons (O…O: 2.741(7) Å) that self-assemble to form tapes along the b axis. The
homodimers further hydrogen bond to crystallographically independent DMP molecules
via an R33(7) ring motif (Fig. 2.4a).

The third hydroxyl moiety of the gallic acid

molecule interacts with the basic nitrogen of the second crystallographically independent
DMP molecule and the phenolic moiety of a GAL molecule to generate a trimeric ring
motif, R33(9) (Fig. 2.4b). The crystal packing is a two dimensional network (Fig. 2.4c).
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(a)

(b)

(c)
Fig. 2.4: (a) Phenolic homodimers of GAL molecules acts as a donor and an acceptor to
DMP molecules (b) R33(9) trimeric motif involving two GAL molecules and a DMP
molecule (c) Crystal packing in GALDMP reveals a 2D network of GAL and DMP
molecules.

GALADN:

The crystal structure of GALADN reveals the self-assembly of GAL and

ADN molecules in the monoclinic space group P21/c. The carboxylic acid moieties of
GAL molecules and the aminopyridine moieties of ADN molecules form R22(8)
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supramolecular heterosynthons (N…O: 2.880(17) Å; O…O: 2.644(78) Å) to generate
chains. These chains are interconnected through the formation of phenolic homodimers
of GAL molecules (O…O: 2.701(11) Å, Fig. 2.5). In addition, the exterior H-bond
donor and acceptor sites of the phenolic homodimers are exploited by ADN molecules of
adjacent chains to generate a 3D network.

Fig 2.5: Crystal packing in GALADN reveals form H-bonded interactions between the
carboxylic acid moiety of GAL molecules and the aminopyridine moiety of ADN
molecules.

GALURE: GAL and URE molecules crystallize in the monoclinic space group P21/c
with one molecule of each in the asymmetric unit. The crystal structure reveals that GAL
and URE molecules form carboxylic acid-amide supramolecular heterosynthons (O…O
2.528(1)Å, N…O:

2.996(1) Å).

hydrogen bonds (N…O:

These heterodimers are cross linked by NH…OH

3.005(1) Å) to form tapes.

The heterodimers are linked

perpendicularly to adjacent tapes by accepting a hydrogen bond from the amine and
phenolic moieties (O…O: 2.701(1) Å; N…O: 2.826(1) Å).

Additionally, the phenolic

moiety of the GAL molecule from the adjacent tape accepts a bifurcated hydrogen bond
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from the phenolic moiety of the GAL molecule and the amine moiety of the URE
molecule (O…O: 2.835(1) Å; N…O: 2.984(1) Å, Fig. 2.6).

Fig. 2.6: Crystal packing in GALURE reveals molecular tapes of heterodimers of GAL
and URE molecules.

GALGAH: The crystal structure of GALGAH contains two independent molecules of
GAH molecules and one independent molecule of GAL in the unit cell. The GAL
molecules form undulating chains sustained by carboxylic acid supramolecular
homosynthons (O…O: 2.610(1) Å) and phenolic supramolecular homosynthons (O…O:
2.723(1) Å). This undulating chain of homodimers is absent in both the anhydrous and
hydrated forms of GAL. An independent GAH molecule acts as both a hydrogen bond
donor and acceptor towards the phenolic homodimers by forming a tetrameric motif
(NH…OH: 2.935(1) Å, OH…O: 2.635(1) Å,) to connect each chain, thereby forming a
sheet (Fig. 2.7a). The other GAH molecule interacts with the GAL chains via OH…O
hydrogen bonds (O…O: 2.748(1) Å) and further connect the sheets above and below
through amide-amide supramolecular homosynthons (N…O: 2.854(1) Å, Fig. 2.7b).

53

(a)

(b)
Fig. 2.7: (a) Crystal packing in GALGAH reveals undulating tapes sustained by dimers
of GAL molecules linked by GAH molecules to form sheets (b) Illustration of sheets
interconnected by homodimers of GAH molecules.

FERADN: The crystal structure of FERADN reveals that FER and ADN molecules in
the unit cell. FER and ADN molecules form two point supramolecular heterosynthons
between the acid moiety of FER and the amine and basic nitrogen of the ADN molecule
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to form 1-D chains (NH…O: 2.839 (1)Å; OH…O: 2.692(1) Å, Fig. 2.8a). Adjacent
chains are cross linked by hydrogen bonding interactions between one FER molecule and
two ADN molecules via R33(10) motifs to result in an interpenetrated three dimensional
network (Fig. 2.8b).

(a)

(b)
Fig. 2.8: (a) Crystal packing in FERADN reveals two point recognition supramolecular
heterosynthons between the acid moiety of FER molecule and the amine and the basic
nitrogen moiety of the ADN molecule (b) Crystal packing of FERADN is that of a 3D
interpenetrated network.
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FERINZ: FER and INZ crystallize in space group P-1 with two molecules of each
component in the asymmetric unit. The crystal structure of FERINZ is sustained by the
robust COOH…Nbasic supramolecular heterosynthons (O…N: 2.636(5) Å, Fig. 7a). The
INZ molecules interact via NH…O (N…O: 2.968(7) Å) supramolecular homosynthons to
form R22(10) dimers (Fig. 2.9a). The intermolecular H-bonding generates a herring bone
pattern as presented in Fig. 2.9b.

(a)

(b)
Fig. 2.9: (a) Crystal packing in FERINZ sustained by COOH…Nbasic supramolecular
heterosynthons (b) Herring bone pattern of FERINZ.
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FERURE:

FER and URE molecules form a 1:2 adduct that crystallizes in the

monoclinic space group P21/c.

Both independent URE molecules form amide-amide

supramolecular homosynthons that generate tapes along the b axis. The NH…O bond
distances are 2.945(3)Å and 2.936(3)Å for the first independent URE molecule and
2.982(3)Å and 2.951(3)Å for the second independent URE molecule. The homodimers
are further interconnected through a two point hydrogen bond between the amine
moieties of URE and the hydroxyl and methoxyl moieties of FER ((N…O: 2.986(2)Å,
N…O: 3.023(2)Å, Fig. 4a) at a dihedral angle of 77.33o. In addition, the carbonyl moiety
of the URE molecule accepts a hydrogen bond from the carboxylic acid moiety of FER
(Fig. 2.10).

Fig. 2.10: Crystal packing in FERURE reveals amide-amide supramolecular
homosynthons between URE molecules to generate tapes that are interconnected by FER
molecules.
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FERGAH:

The 2:2 cocrystal of FER and GAH is sustained by chains of GAH

molecules via amide-amide supramolecular homosynthons (N…O: 2.987(1) Å; N…O:
2.225(1) Å). The chains of GAH molecules are interconnected by FER molecules
through OH…O hydrogen bonding (O…O: 2.615(1)Å) resulting in the formation of a
sheet as illustrated in Fig. 2.11.

Fig. 2.11: Crystal packing in FERGAH reveals molecular tapes of amide-amide
supramolecular homosynthons between GAH molecules interconnected by FER
molecules.

FERTBR: The crystal structure of FERTBR . H2O reveals a 1:1 cocrystal monohydrate
which crystallizes in the monoclinic space group C2/c. The crystal structure consists of
FER and TBR molecules that form acid-imide supramolecular heterosynthons (N…O:
2.858(3) Å, O…O: 2.602(3) Å) interconnected by water molecules to form discrete 6component supramolecular assemblies (Fig 2.12).
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Fig 2.12: Crystal packing of FERTBR . H2O reveals that FERTBR heterodimers are
connected by water molecules.

2.4

Discussion
Six cocrystal formers were studied herein and they afforded five pairs of

cocrystals of gallic acid and ferulic acid (INZ, ADN, DMP, URE and GAH). The
eleventh FERTBR.H2O can also be paired since the crystal structure of gallic acid and
theobromine dihydrate has been reported elsewhere.40 The data presented herein shows
that phenolic acids can generally be considered as reliable cocrystal formers with
molecules that contain a basic nitrogen/amide moiety. A CSD survey of phenolic acids
(i.e. hydroxylated derivatives of benzoic acids and cinnamic acids) resulted in 324
entries, of which 159 are cocrystals. However, the number of entries of gallic acid and
ferulic acid cocrystals are 8 and 5 entries respectively.
The reliability of the supramolecular synthon approach as a design tool for the
preparation of cocrystals has been systematically explored in several studies. 25,27, 41
Carboxylic acids are known to form persistent supramolecular heterosynthons with
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weakly basic nitrogen or amide moieties. Studies have also focused upon weakly acidic
OH groups and their ability to form supramolecular heterosynthons with basic nitrogen
and carboxylate moieties have been established. For example, it has been reported that
the probability of occurrence of COOH…Nbasic in the presence and absence of competing
functional moieties are 77% and 97%, respectively.25 The cocrystals reported herein
focus upon the hierarchy of supramolecular synthons when phenolic and carboxylic acid
moieties are present in the same molecule. GALADN, GALDMP, GALINZ, FERINZ
and FERADN all exhibit the carboxylic acid-basic nitrogen supramolecular
heterosynthon.

The COOH…Nbasic bond distance range is 2.588(4) to 2.692(1) Å and

reveals the robustness of the COOH…Nbasic supramolecular heterosynthon. The bond
distance range of carboxylic acid aromatic nitrogen supramolecular heterosynthon ranges
from 2.5 to 3.0 with a mean distance of 2.652(2). However, in FERTBR.H2O, the
COOH…Nbasic supramolecular heterosynthon is absent and is replaced by the acid-imide
supramolecular heterosynthon. This anomaly may be attributed to the presence of the
water molecule. Indeed, a CSD survey of TBR cocrystals with carboxylic acids reveals
five entries: CSATBR, HIJYAB, HIJYEF, NURYUV and MUPPET. HIJYAB and
NURYUV formed the COOH…Nbasic supramolecular heterosynthon and the TBR
molecules formed the imide homodimers. Similarly, crystal structures of CSATBR and
HIJYEF are sustained by the COOH…Nbasic supramolecular heterosynthon and also form
the acid-imide supramolecular heterosynthon due to the presence of a second carboxylic
acid moiety. In contrast, MUPPET, a cocrystal consisting of gallic acid, theobromine
and two water molecules, did not form the COOH…Nbasic supramolecular heterosynthon,
instead water molecules are hydrogen bonded to the imidazoyl moiety and the acid-imide
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supramolecular heterosynthon is formed. In both FERTBR.H2O and GALTBR.2H2O, a
six component supramolecular assembly between two FER or GAL molecules, two TBR
molecules and water molecule(s) is observed. Indeed, it has been asserted that, although
carboxylic acids and phenols form supramolecular synthons with aromatic nitrogen even
in the presence of competing functional groups, the supramolecular synthons exhibited
between carboxylic acids, phenols and water molecules are rather diverse.34
Furthermore, the promiscuity of waters of hydration in terms of the supramolecular
heterosynthons they exhibit is exemplified by the four polymorphs of gallic acid
monohydrate.42
GALURE exhibits the acid-amide supramolecular heterosynthon but it is absent
in FERURE, FERGAH and GALGAH. FERGAH and FERURE both exhibit infinite
chains of self-complementary amide-amide supramolecular homosynthons. GALGAH
consists of two independent GAH molecules, one of which retained the amide-amide
supramolecular homosynthons whereas the other hydrogen bonds to the phenolic
homosynthons. Infantes et al, studied the probability of hydrogen bonding interactions of
various functional groups and it was demonstrated that the relative strength of
supramolecular homosynthons is in the order of: amides > acids > alcohols functional
groups.43 However, several studies show that in the presence of carboxylic acids, there is
84% probability of the occurrence of the acid-primary amide supramolecular
heterosynthon.24,25 Indeed, a recent study concerning the hydrogen bonding binding
energy between primary amides vs that between acid and primary amides indicated that
the acid-amide interaction is stronger than the amide-amide interaction.44 These studies
concentrated on primary amides and the question arises if this also holds true for
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secondary amides. A CSD analysis of the occurrence of the acid-secondary amide
supramolecular heterosynthon indicates 3.8% occurrence in the absence of competing
functional groups (Table 3).

Further analysis reveals that the acid supramolecular

homosynthon and the amide supramolecular homosynthon occur 21.7% and 19.6%,
respectively.
The phenolic supramolecular homosynthon is observed in cocrystals of
GALADN, GALINZ, GALDMP and GALGAH. A CSD survey reveals that out of 466
entries of organic molecules with a catechol functional moiety, 94 (20.1%) form phenolic
homodimers. Elimination of competing functional moieties resulted in 13 entries, and 8
(61.5%) formed phenolic homodimers.

The rule of thumb in hydrogen bonding

according to Etter is that hydrogen bonds form in a hierarchical fashion whereby the best
hydrogen bond donor and acceptor preferentially interact with each other, followed by
the second best hydrogen bond donor and acceptor, etc.45 Indeed, the crystal structures of
GALADN, GALDMP and GALINZ are consistent with Etter’s rule since the phenolic
homodimers are presumably a consequence of the formation of the robust COOH…Nbasic
supramolecular heterosynthon.

2.5

Conclusion
In summary, this work has demonstrated the use of gallic acid and ferulic acid as

reliable cocrystal formers with molecules containing a basic nitrogen/amide moiety. Of
the six cocrystal formers studied; five pairs of cocrystals of gallic acid and ferulic acid
with INZ, ADN, DMP, URE and GAH were afforded. FERTBR.H2O can also be
paired since GALTBR.2H2O was previously reported. The crystal structures of the
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anhydrous cocrystals reveal the hierarchy of the COOH…Nbasic supramolecular
heterosynthon in the presence of phenolic moieties. However, FERTBR.H2O illustrates
the challenges that may arise when a water molecule is incorporated in the crystal lattice
since crystalline hydrates are capricious in terms of the supramolecular heterosynthon
they exhibit.
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Chapter 3: Crystal Engineering of Isostructural Quaternary Multi-Component
Crystal Forms of Olanzapine.

3.1

Introduction
Crystal engineering, 1,2 has matured into a well-recognized aspect of solid-state

chemistry research and is focused on the design of novel crystalline solids with tunable
physicochemical properties.

The selection of a suitable crystal form of an active

pharmaceutical ingredient (API) is particularly relevant to oral drug delivery, 3 and it
profoundly influences the development and performance of the API. Crystal forms of
APIs have spanned polymorphs,4 solvates,5 hydrates6 and more recently, pharmaceutical
cocrystals.7,8
Pharmaceutical cocrystals can be defined as multiple component crystals in which
at least one component is molecular and a solid at room temperature (the cocrystal
former) and forms a supramolecular synthon with a molecular or ionic API.
Pharmaceutical cocrystals have emerged as a new paradigm in pharmaceutical solid form
development to diversify the range of crystal forms exhibited by APIs, allowing
opportunities for improved performance characteristics and extend the product life and
patent coverage of the API.9,10 Most importantly, pharmaceutical cocrystals can enhance
physicochemical properties of APIs such as solubility, 11 stability 12 and mechanical
properties 13 while preserving the intended intrinsic activity of the API. In addition,
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pharmaceutical cocrystals have been incorporated with other techniques used to modulate
physicochemical properties as noted in the examples of nanocrystalline cocrystals 14 and
cocrystals of salts.15
Pharmaceutical cocrystals are amenable to design due to the ubiquitous nature of
APIs, in that, they possess exterior functional groups that readily engage in
supramolecular synthons with a wide variety of pharmaceutically acceptable cocrystal
formers. However, this semi-empirical approach becomes challenging for APIs that
exhibit conformational flexibility and/or possess multiple functional groups.

16

In

addition, the design or engineering of compositions with more than two unique
components becomes challenging due to the functional diversity introduced by each
component.
Olanzapine

(2-methyl-4-(4-methyl-l-piperazinyl)-10H-thieno-[2,3b][1,5]benzo-

diazepine), a BCS 17 class II (low solubility, high permeability) API was selected as a
crystal engineering candidate. Olanzapine is a widely prescribed atypical antipsychotic
drug marketed under the trademark name Zyprexa® by Eli Lilly and Company. The drug
is therapeutically effective in treating psychiatric disorders such as schizophrenia and
manic episodes associated with bipolar disorder. 18 Olanzapine has been shown to be
effective in the reduction of not only positive symptoms (hallucinations and delusions),
but also negative and cognitive symptoms (social and emotional withdrawal) in acute and
relapsing schizophrenics.19 Crystal forms of olanzapine are well-documented and include
six anhydrous polymorphs, 20 , 21 , 22 , 23 three polymorphic dihydrates, 24 two polymorphic
sesquihydrates, several solvated forms, 25 mixed solvates and hydrates, 26 salts and an
amorphous form. 27

Much research has been done to develop novel crystal forms of
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olanzapine. Reutzel-Edens et al discussed the polymorphism of olanzapine dihydrate and
the structural relationship between the anhydrates and hydrates.28 Nangia et al showed
that the solubility of olanzapinium monomaleate and dimaleate salts was 225-550 times
greater than that of free base olanzapine.29
Isostructural cocrystals, i.e. crystal forms that exhibit the same or similar crystal
structure,30 have been reported in the literature.31 These crystal forms, primarily binary
cocrystals, are generally designed by interchanging structurally equivalent functional
groups such as chloride/methyl exchange, Br/I or CH/N. 32 The design and successful
synthesis of isostructural olanzapine cocrystals is remarkable in the context that it
contains four distinct molecular entities. Indeed, it has been shown recently that the
subtle changes in the chemical composition of the API, i.e. swapping the sodium for the
potassium cation, can result in significant and unpredictable changes in both the packing
arrangement and physicochemical properties of the salt of the API. 33 The design of
isostructural cocrystals based on the analysis of the existing crystal forms offers unique
opportunities to systematically fine-tune the physicochemical properties of the API by
controlling the molecular arrangement in the solid state. This article illustrates a design
strategy to construct multi-component crystal forms of olanzapine a priori from the
systematic analysis of existing crystal structures, culminating in the formation of multicomponent compositions with four unique molecules.

3.2

Materials and Methods

3.2.1

Materials

Olanzapine was obtained from Alkermes Inc. and used without further purification.
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Cocrystal formers were purchased from commercial vendors and used without further
purification (Figure 3.1). Solvents purchased from commercial vendors were distilled
before use. All cocrystals were analyzed by powder X-ray diffraction (PXRD), and
single crystal X-ray analysis where applicable.

Figure 3.1: Chemical structures of olanzapine and cocrystal formers used herein.

3.2.2

Preparation of Cocrystals

Olanzapine ·Nicotinamide Isopropyl acetate Tetrahydrate, OLANAM.IPA.4H2O:
Olanzapine (40 µL of a 25mg/ml stock solution) and nicotinamide (37.6 µL of a 20
mg/mL stock solution) were added to a glass vial and the solvent was dried under
nitrogen flow. Isopropyl acetate was added to the mixture and the sealed vial was heated
at 70 oC for two hours. The solution was then cooled at 5 oC for 24 hours. The solution
was concentrated to 50 µL total volume, recapped and left at 5 oC for an additional 24
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hours. Large yellow plates of the OLANAM.IPA.H2O were collected and allowed to
dry at ambient conditions.
Olanzapine ·Salicylamide Isopropyl acetate Tetrahydrate OLASAM.IPA.H2O:
Olanzapine (7.5 mg, 0.024 mmol) and salicylamide (5.1 mg, 0.037 mmol) were dissolved
in 1 mL isopropyl acetate and heated at 90 oC until all the solid material was dissolved.
The vial was sealed and the solution was allowed to slowly evaporate at 5 oC. After three
days, large yellow plates of the OLASAM.IPA.H2O were collected by gravimetric
filtration and dried at room temperature.
Olanzapine

·p-Hydroxybenzamide

Isopropyl

acetate

Tetrahydrate,

OLAPHBNZ.IPA.4H2O: Olanzapine (7.5 mg, 0.024 mmol) and p hydroxybenzamide
(7.0 mg, 0.051 mmol) were dissolved 1 mL isopropyl acetate and heated at 90 oC until all
the solid material was dissolved. The sealed vial was sealed was allowed to slowly
evaporate at 5 oC. After eleven days, yellow plates of the OLAPHBNZ.IPA.H2O were
collected by gravimetric filtration and dried at room temperature.

3.2.3

Methods

Powder X-ray diffraction (PXRD): Bulk samples were analyzed by powder X-ray
diffraction with a Bruker AXS D8 powder diffractometer. Experimental conditions: Cu
Kα radiation (λ = 1.54056 Ǻ); 40 kV; 30 mA; scanning interval 3–40° 2θ; time per step
0.5s. The experimental PXRD patterns and calculated PXRD patterns from single crystal
structures were compared to confirm that the composition of the bulk materials was
consistent with that of the single crystal used for X-ray crystallography.
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Single Crystal X-ray Diffraction Analysis: Single crystal X-ray data were collected
using Bruker-AXS SMART-APEXII CCD diffractometer using CuKα radiation, λ =
1.54178 Å for OLASAM.IPOAc.H2O and Mo Kα radiation (λ = 0.71073 Å) for
OLANAM.IPOAc.H2O. Indexing was performed using APEX2 34 (Difference Vectors
method). Data integration and reduction were performed using SaintPlus 6.01. 35
Absorption correction was performed by multi-scan method implemented in SADABS.36
Space groups were determined using XPREP implemented in APEX2. The structure was
solved using SHELXS-97 (direct methods) and refined using SHELXL-97 (full-matrix
least-squares on F2) contained in APEX2 and WinGX v1.70.01 37 , 38 , 39 , 40 [4,5,6,7]
programs

packages.

All

non-hydrogen

atoms

were

refined

anisotropically.

Hydrogen atoms of water molecules and –NH groups for OLANAM.IPOAc.H2O were
found in the Fourier difference map and included in the refinement process using distance
restraints (DFIX) with isotropic thermal parameters: Uiso(H) = 1.5Ueq(-NH,-OH). All
remaining hydrogen atoms were placed in geometrically calculated positions and
included in the refinement process using riding model with isotropic thermal parameters:
Uiso(H) = 1.2Ueq(-CH, -CH2), Uiso(H) = 1.5Ueq(-OH, -CH3).
Hydrogen atoms of water molecules and –NH groups for OLASAM.IPOAc.H2O were
found in the Fourier difference map and included in the refinement process using distance
restraints (DFIX, SADI) with isotropic thermal parameters: Uiso(H) = 1.5Ueq(-NH,-OH).
All remaining hydrogen atoms were placed in geometrically calculated positions and
included in the refinement process using riding model with isotropic thermal parameters:
Uiso(H) = 1.2Ueq(-CH, -CH2), Uiso(H) = 1.5Ueq(-OH, -CH3). Crystallographic data
and hydrogen bond parameters are presented in the appendix 4.
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3.3

Results

Crystal

Structures

of

OLANAM.IPA.4H2O

and

OLASAM.IPA.4H2O:

OLANAM.IPA.4H2O and OLASAM.IPA.4H2O crystallize in the monoclinic space
group P21/c where each cocrystal contain two OLA molecules, four water molecules, an
isopropyl acetate molecule and one molecule of the cocrystal former (NAM or SAM).
The crystal structures of OLANAM.IPA.4H2O and OLASAM.IPA.4H2O reveal a twodimensional hydrogen-bonded network where four water molecules hydrogen bond to
each other to form a tetrameric catemer. This tetrameric catemer interacts with four
OLA molecules by donating four hydrogen bonds and accepting two hydrogen bonds
(Figs. 3.2a and 3.2b). The isopropyl acetate molecules and the NAM/ SAM terminate the
tetrameric catemer of water molecules via OH…O and NH…O hydrogen bond
interactions. NAM/ SAM molecules form amide homodimers along the c axis (Figs. 3.3a
and 3.3b). Olanzapine molecules are aligned in a herring bone pattern and are stacked in
an eclipsed fashion (Figs. 3.4a and 3.4b). Single crystals suitable for X-ray structure
determination

were

not

obtained

for

OLAPHBNZ.IPA.4H2O.

However,

OLAPHBNZ.IPOAc.4H2O is presumably isostructural to OLANAM.IPA.4H2O and
OLASAM.IPA.4H2O since the powder pattern obtained was found to be similar to the
powder patterns of OLANAM.IPA.4H2O and OLASAM.IPA.4H2O (appendix 4).
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(a)

(b)

Figure 3.2: Crystal packing view along a axis of (a) OLANAM.IPA.4H2O and (b)
OLASAM.IPA.4H2O exhibiting a tetrameric catemer of water molecules that is
hydrogen bonded to four OLA molecules. The tetrameric catemer of water molecules
offers 4 hydrogen bond donors and 2 hydrogen bond acceptors to complement a pair of
olanzapine molecules. The isopropyl acetate and the cocrystal former (NAM or SAM)
hydrogen bond to each side of the tetrameric catemer of water molecules.

(a)

(b)

Figure 3.3: Crystal packing view along c axis of OLANAM.IPA.4H2O and (b)
OLASAM.IPA.4H2O showing how the tetrameric catemers of water molecules are
terminated by the cocrystal former (NAM or SAM). The NAM and SAM molecules
form dimers to extend the structure. In each case, two olanzapine molecules are omitted
for clarity.
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(a)

(b)

Figure 3.4: Crystal packing of OLANAM.IPA.4H2O and (b) OLASAM.IPA.4H2O
showing a herring bone pattern of pairs of olanzapine enantiomers hydrogen bonded to
four water molecules. NAM, SAM and isopropyl acetate molecules omitted for clarity.

Anhydrate

Dihydrate

Sesquihydrate

UNOGIN
UNOGIN01

AQOMAU
AQOMAU01
AQOMAU02

AQOMEY
AQOMEY01

Solvates

Mixed hydrates and solvates

Salts

UNOGOT
(methanol)

CAYTUS
(DMSO monohydrate)

JIXROY
(olanzapinium benzoate)

WEXQAS
(dichloromethane)

ELEVOG
(methanol monohydrate)

TAQNUV
(olanzapinium nicotinate)

WEXPUL
(butan-2-ol monohydrate)

AMIYUR
(olanzapinium maleate
(1:1))

WEXQEW
(ethanol dihydrate)

AMIZAY
(olanzapinium maleate
(1:2))

Table 3.1: Refcodes for crystal structures of olanzapine deposited in the CSD.
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Figure 3.5: Crystal packing of olanzapine anhydrate form I showing olanzapine
enantiomers sustained by NH…N hydrogen bond interactions along the c axis.

3.4

Discussion

A critical step in the design of cocrystals is the study of crystal packing and hydrogen
bonding patterns exhibited within the crystal structure of the target molecule. Analysis of
the crystal structures of olanzapine deposited in the CSD reveals an anhydrate; three
polymorphs of olanzapine dihydrate; two polymorphs of olanzapine sesquihydrate;
methanol and dichloromethane solvates; four mixed solvates and hydrates; and salts with
benzoate, nicotinate and maleate anions (Table 3.1). Observation of the crystal packing
in the crystal forms of olanzapine reveals pairs of olanzapine molecules where olanzapine
adopts mirror-related conformations.41 In olanzapine anhydrate, these pairs of olanzapine
molecules are connected by NH…N hydrogen bond interactions (Fig. 3.5). However in
the solvated and salt forms of olanzapine, the NH…N interaction is disrupted by solvent
molecules or anions occupying sites between the pairs of olanzapine molecules.
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Many of these crystal forms are isostructural and can be categorized according to
their crystal packing arrangement and crystallographic unit cell parameters are denoted
packing A, packing B, packing C and packing D (Tables 4-7).
Packing A is exhibited in the crystal structure of olanzapine dihydrate form D
(AQOMAU, Fig. 3.7). In packing A, supramolecular heterosynthon 1 (Fig. 3.6a) is
observed where the water molecules are arranged as a cyclic tetramer between the pairs
of olanzapine molecules such that it offers four hydrogen bond donors and two hydrogen
bond acceptors. The number of hydrogen bond donors and acceptors is complementary
to a pair of olanzapine molecules since olanzapine possesses one hydrogen bond donor
and two hydrogen bond acceptors. The pairs of olanzapine molecules form a herring
bone pattern and the sheets are eclipsed to each other (Fig. 3.7b).
Packing B is exhibited in three isostructural crystal forms of olanzapine: AQOMAU01
(dihydrate form B), AQOMEY01 (sesquihydrate form II) and UNOGOT (methanol
solvate). Packing B exhibits a three dimensional network where the solvent molecules lie
between pairs of olanzapine molecules and hydrogen bonds to four olanzapine molecules
(Figure 3.8).

In all three crystal forms, the pairs of olanzapine molecules are aligned

along the crystallographic a axis in a herring bone pattern to form sheets that are stacked
in an eclipsed manner. Supramolecular heterosynthon 2 (Fig. 3.6b) is observed in the
hydrated crystal forms AQOMAU01 and AQOMEY01 where the water molecules are
arranged as a catamer and offers the same number of hydrogen bond donors and
acceptors similar to supramolecular synthon 1 to match a pair of olanzapine molecules.
In the methanol solvate (UNOGOT), a pair of methanol molecules lies between the pairs
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of olanzapine molecules and hydrogen bonds to four olanzapine molecules via NH…O
and OH…O interactions.
Packing C is exhibited in various crystal forms: AQOMEY (sesquihydrate form I),
AQOMAU02 (dihydrate form E), CAYTUS (DMSO solvate) and ELEVOG (methanol
monohydrate). Similar to packing A and B, the solvent molecules occupy sites between
the pairs of olanzapine molecules to form bridges that hydrogen bonds to four olanzapine
molecules. Supramolecular heterosynthon 2 is also observed in the hydrated crystal
forms. The difference between packing B and packing C is the orientation of adjacent
sheets where they are stacked in a staggered fashion (Figure 3.9).
Packing D is exhibited in salts of olanzapine with benzoate (JIXROY) and nicotinate
(TAQNUV) anions. Analysis of the crystal structures reveals the alignment of the pairs
of olanzapine molecules along the c axis (Figure 3.10).

The pairs of olanzapine

molecules are connected via charge assisted interactions formed between the carboxylate
of the benzoate and nicotinate anion and the ammonium of the olanzapine cation.

Figure 3.6: Two types of supramolecular heterosynthon exhibited in crystal structures of
olanzapine dihydrate.
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REF
CODE

Compo a (Å)
und

AQOM Dihydr
AU
ate

9.927
(5)

b (Å)

c (Å)

α (o)

β (o)

γ (o)

Volum
e

10.095
(5)

10.514
(6)

84.71
(1)

62.66
(<1)

71.18
(<1)

884.00
1

Space
Grou
p
P-1

Table 3.2: Crystal forms of olanzapine that exhibits packing A.

REF
CODE
AQOM
EY01
AQOM
AU01
UNOG
OT

REF
CODE
AQOME
Y
AQOMA
U02
CAYTU
S

ELEVO
G

Comp a (Å)
b (Å)
c (Å)
ound
Sesqui 10.040 12.900 14.510
hydrat
(2)
(3)
(3)
e
Dihyd 9.869 12.716 14.385
rate
(1)
(1)
(1)

α (o)

β (o)

γ (o)

90

92.97
(<1)

90

90

92.97
(<1)

90

Volu
me
1802.8
10

Space
Group
P21/c

1802.8
10

P21/c

Metha 10.207 12.440 14.278
90
92.60
90
1811.0
nol
(3)
(4)
(5)
(3)
84
solvat
e
Table 3.3: Crystal forms of olanzapine that exhibits packing B.

P21/c

Comp a (Å)
b (Å)
c (Å)
ound
Sesqui 25.130 12.238 14.912
hydrat 9 (2)
(1)
(1)
e
Dihyd 24.520 12.350 15.218
rate

α (o)

β (o)

γ (o)

90

124.98
(<1)

90

90

125.82

90

Volu
me
3757.2
14

Space
Group
C2/c

3736.2
81

C2/c

DMS 24.584 12.534 15.153
90
125.45
90
3803.4
O
(4)
(1)
(3)
(1)
30
solvat
e
Metha 25.359 11.973 15.609
90
127.58
90
3753.7
nol
(<1)
(<1)
(<1)
(<1)
71
monoh
ydrate
Table 3.4: Crystal forms of olanzapine that exhibits packing C.

C2/c
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C2/c

REF
CODE
TAQNU
V

JIXROY

(a)

Comp
ound

a (Å)

b (Å)

α (o)

c (Å)

β (o)

γ (o)

Volu
me

Space
Group

Olana 9.296 11.242 12.000 63.16 87.48 83.73 1111.4
zapine
(1)
(1)
(1)
(<1)
(<1)
(<1)
42
nicotin
ate
Olanz 9.257 11.222 12.063 64.59 87.57 83.25 1124.7
apine
(<1)
(<1)
(<1)
53
benzo
ate
Table 3.5: Crystal forms of olanzapine that exhibits packing D.

P-1

P-1

(b)

Figure 3.7: (a) Crystal structure of olanzapine dihydrate form D exhibiting packing A
where a cyclic tetramer of water molecules hydrogen bonds to four olanzapine molecules
along the b axis. (b) Sheets of olanzapine molecules eclipse one another; water
molecules deleted for clarity.
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(a)

(b)

(c)

(d)
Figure 3.8: Crystal packing of (a) olanzapine dihydrate form B (b) olanzapine

sesquihydrate form II and (c) olanzapine methanol solvate exhibiting packing B, wherein
the solvent molecules are arranged such that they hydrogen bond to four olanzapine
molecules. (d) Illustrates sheets that are arranged in a herring bone pattern and stack in an
eclipsed manner; solvent molecules deleted for clarity.

82

(a)

(b)

(c)

(d)

Figure 3.9: Crystal forms of (a) olanzapine sesquihydrate form I (b) olanzapine DMSO
solvate and (c) olanzapine methanol monohydrate exhibiting packing C where the solvent
molecules form bridges to hydrogen bond to four olanzapine molecules. (d) Illustrates
adjacent sheets that stack in a staggered manner; solvent molecules deleted for clarity.
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(a)

(b)
Figure 3.10: Packing D exhibiting olanzapine cation interacts with nicotinate and
benzoate anions via charge assisted NH…COO- hydrogen bonds along the a axis.

Crystal Engineering of Isostructural Cocrystals of Olanzapine: The formation of
centrosymmetric pairs of olanzapine molecules is observed in crystal forms that exhibit
packing A, B, C and D. Analysis of these crystal forms reveals the solvent molecules
always arrange themselves between pairs of olanzapine molecules and hydrogen bonds to
four olanzapine molecules irrespective of the solvent molecule. It has been asserted that
water molecules are promiscuous in terms of the supramolecular synthons they it exhibit,
as well as resulting structural stability and stoichiometry.42 Indeed, the water molecule
has been described as chameleon-like due to its small size and versatile hydrogen
bonding capabilities.

For example, gallic acid monohydrate, the first tetramorphic

hydrate for which fractional coordinates have been determined, exhibits different
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supramolecular synthons and crystal packing in each polymorph. In contrast, analysis of
the polymorphic forms of olanzapine dihydrate for which coordinates have been
determined reveals that the water molecules arrange to offer four hydrogen bond donors
and two acceptors to complement a pair of olanzapine molecules (Figure 5). Therefore, it
can be presumed that the pairs of olanzapine molecules are the supramolecular building
blocks of the crystal structure and therefore dictate the supramolecular assembly of the
other components within the crystal. This supramolecular building block was therefore
exploited to yield isostructural cocrystals of olanzapine consisting of four chemical
entities: olanzapine, the cocrystal former, an iso-propyl acetate solvent molecule and
four water molecules.
Crystal structures of OLANAM.IPA.4H2O and OLASAM.IPA.4H2O reveal the
presence of a tetrameric catemer of water molecules as exhibited in the solvated crystal
forms of olanzapine. The presence of this tetrameric catemer of water molecules within
the crystal lattice results in an imbalance of the number of hydrogen bond donors and
acceptors such that there is an excess of a single hydrogen bond donor and a hydrogen
bond acceptor. The excess hydrogen bond donor and acceptor become satisfied by the
incorporation of the solvent molecule and the cocrystal former to afford four hydrogen
bond donors and two hydrogen bond acceptors to match a pair of olanzapine molecules.
The underlying principle in the synthesis of isostructural cocrystals of olanzapine is that
the persistence of the pairs of olanzapine molecules and the tetrameric catemer of water
molecules allows for the substitution of cocrystal formers that are structurally consistent
without altering the crystal packing.
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Total number of entries

No. of entries

% of structures

152

100

Entries where one chemical
45
29.6
entity is a solid at ambient
temperature
Entries with two chemical
85
55.9
entities that are solids at
ambient temperature
Entries with three chemical
17
11.1
entities that are solids at
ambient temperature
Entries with four chemical
5
3.8
entities that are solids at
ambient temperature
* Conquest 1.13, Nov 2011 update, only organics, 3D coordinates known, R ≤ 7.5, No
ions.
Table 3.6: CSD statistics of crystal forms containing four distinct molecular chemical
entities.

CSD statistics of crystal structures that contain four distinct molecular chemical
entities
A CSD analysis was conducted to evaluate the number of crystal forms that
contains four distinct chemical entities to reveal a total of 152 hits. These structures were
further divided into four categories where at least 1 component was solid, at least two
components were solid, at least three components were solid and at least four components
were solid (Table 3.6).
There are 45 entries where one chemical entity was solid at ambient temperature
whereas 85 of the 152 entries fall into the category where at least two chemical entities
are solid at ambient temperature. Analysis of the categories where all three and four
chemical entities are solid reveals 17 and 5 entries respectively. Cocrystals of olanzapine
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reported herein fall into the category where two chemical entities are solid at ambient
temperature. Of the 152 entries, only three crystal forms, MESRUX, OHUXAQ and
POHXUG contain a molecule that exhibits biological activity. OHUXAG contains only
one molecule that is solid at room temperature and MESRUX and POHXUG contains
two and three molecules that are solid at room temperature respectively. Analysis of
crystal forms containing four chemical entities reported in the CSD reveal that few
exhibit isostructurality, notably CIKWAV, CIKWEZ, CIKWED (where two chemical
entities are solid), ROBHAS, ROBHEW, ROBHIA (where three chemical entities are
solid), QUFZIB and QUFZOH (where four chemical entities are solid). Most of these
structures are host-guest inclusion compounds where isostructurality is achieved through
the exchange of guest molecules that are loosely held in the crystal structure. A literature
survey of isostructural cocrystals reveals mainly two component crystal forms sustained
by hydrogen and halogen bonding networks.32,

43

Indeed it has been reported that

isostructural structures rarely include more than two members due to the close packing of
molecules in crystalline solids.44 However to the best of our knowledge, this is the first
reported isostructural four component crystal forms that contain water and solvent
molecules.

3.5

Conclusion
In summary, this study has shown how the systematic analysis and understanding

of existing crystal structures of olanzapine facilitates the synthesis of four component
isostructural cocrystals of olanzapine. These cocrystals are relevant as they illustrate that
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in general crystal structures of APIs can be deliberately designed and their
physicochemical properties can be systematically customized.
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Summary
The increasing number of poorly soluble new drug candidates has challenged the
pharmaceutical industry to develop new drug delivery technologies. Pharmaceutical
cocrystals have become an inherent part of drug development as it is one means to
improve the physicochemical and biopharmaceutical properties of the API.

As

pharmaceutical cocrystals play an active role in drug development strategies, several
issues such as their design i.e. the selection of cocrystals former libraries, the challenges
that arise in their design and scale up become of interest.
The research herein focuses on the design of cocrystals in the context of the
selection of the cocrystals former libraries. Typically, cocrystals former libraries include
pharmaceutically acceptable carboxylic acids however this can be expanded to include
compounds such as nutraceuticals, zwitterions and inorganic salts. The phenolic acids,
gallic acid and ferulic acid (a subclass of nutraceuticals) were used as model compounds
since they possess the functional moieties carboxylic acid and phenols. These functional
moieties readily engage in molecular recognition events with complementary functional
groups basic nitrogen, amides and carbonyls.

Therefore, based on the statistical success

rate of supramolecular heterosynthons formed between these complementary functional
moieties and using the concepts of self-assembly, cocrystals formers were selected. The
six cocrystals formers selected yielded 6 pairs of cocrystals with the compounds gallic
acid and ferulic acid respectively. Studies of the crystal packing and supramolecular
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synthons of these cocrystals revealed the hierarchical nature of the COOH…Nbasic
supramolecular heterosynthon. This study has shown that cocrystals can be designed by
first principles of crystal engineering using the concepts of supramolecular chemistry and
self-assembly. It reiterates the fact that a detailed understanding of the supramolecular
synthons formed between functional groups is pivotal in the design of cocrystals.
However, this strategy falls short when a molecule possesses multiple functional groups
and exhibits conformational flexibility.
A crystal engineering strategy was developed to address such compounds using
the model compound, olanzapine.

This design strategy included a comprehensive

analysis of the crystal packing of existing crystal forms of olanzapine. Analysis of the
crystal forms of olanzapine deposited in the Cambridge Structural Database (CSD)
revealed four types of crystal packing. In addition, analysis of the hydrated crystal forms
of olanzapine revealed that the water molecules are arranged such that the number of
hydrogen bond donors and acceptors is complementary to a pair of olanzapine molecules.
This understanding was advantageous to afford four quaternary isostructural multicomponent crystal forms of olanzapine. These crystal forms consist of olanzapine, the
cocrystals former, an iso-propyl acetate solvent molecule and a water molecule. These
cocrystals are relevant as they illustrate that in general crystal structures of APIs can be
deliberately designed and their physicochemical properties can be systematically
customized.
The role of water molecules in crystal engineering was investigated in terms of
the nemesis it presents in the design of crystal forms. Although hydrates represent 10%
of the crystal structures archived in the CSD and numerous hydrates are known for a
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given compound, the question is asked, “In general, can a hydrate be synthesized or
designed intentionally?” In other words, is there anything predictable about hydrates,
that is, their preparation, thermal stability or the supramolecular synthons they exhibit. A
series of cocrystals hydrates were investigated and were categorized according to the
thermal property they exhibit. In addition, a Cambridge Structural Database (CSD)
analysis was conducted in order to address the supramolecular heterosynthons that water
molecules exhibit with two of the most relevant functional groups in the context of active
pharmaceutical ingredients, carboxylic acids, and alcohols. It was concluded that there
was no correlation between the crystal structure and the thermal stability exist in any of
the other categories of hydrate. The CSD analysis suggests that, unlike cocrystals, there
is great diversity in the supramolecular heterosynthons exhibited by water molecules
when they form hydrogen bonds with carboxylic acids or alcohols.
That hydrates can be regarded as the nemesis in crystal engineering can be
reiterated by the isolation of two polymorphic forms of gallic acid monohydrate to give
the first tetramorphic hydrate for which fractional coordinates have been determined.
Analysis of the crystal packing in each form revealed significantly different hydrogen
bonding patterns. Moreover, a CSD survey of polymorphic hydrates exhibited different
supramolecular synthons with respect to the water molecule. Therefore, the promiscuity
of hydrates in terms of the supramolecular synthons they exhibit or their thermal stability
reveals the challenges in crystal engineering.
Future direction should focus on the advancement of the understanding of
cocrystal formation. In addition to the expansion of cocrystal formers, incorporating
phase solubility diagrams is relevant since it defines the thermodynamically stable region
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of the cocrystal in relation to its pure components. Emphasis must be placed on the
physical stability of cocrystals in order to develop scale-up procedures in the manufacture
of cocrystals. Focus should be placed on the low cost scale-up of the cocrystal without
changing its optimized properties and reproducibility.
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Formula
MW
(g/mol)
Crystal
system
Space
group
a (Å)

OLANAM.IPA.4H2O

OLASAM.IPA.4H2O

C45H64N10O7S2

C45H64N10O8S2

921.18

937.17

monoclinic

monoclinic

P21/c

P21/c

14.0961 (12)

14.1966(7)

b (Å)

12.5984 (10)

12.5375(6)

c (Å)
α (deg)
β (deg)
γ (deg)
V / A3
Dc/g cm-3
Z

27.219 (2)
90
97.396 (2)
90
4793.6 (7)
1.276
4

27.4599(15)
90
96.579(3)
90
4855.4

2θ range

1.46 to 25.04

3.13 to 67.47

8457/620

8186 / 594

100(2)

100(2)

0.0676

0.0698

0.1687
1.018
0.171

0.2120
1.010
1.492

Nref./Npar
a
T /K
R1 [I>2σ
(I)]
wR2
GOF
Abs coef

4

Table 1: Crystallographic data and structure refinement parameters for cocrystals of
olanzapine.
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Hydrogen
d (H · · · A) /Å D (D · · · A)/Å
<(DHA)
bond
2.01(2)
2.878(4)
170(4)
OLANAM.IPOAc.H2O
N-HO
1.99(2)
2.865(4)
168(3)
N-HO
1.91(2)
2.829(4)
172(4)
N-HO
2.02(2)
2.926(4)
173(4)
N-HO
2.034(18)
2.909(4)
175(4)
O-HO
1.916(18)
2.771(4)
168(3)
O-HO
2.110(18)
2.956(4)
172(4)
O-HO
1.99(2)
2.840(4)
160(4)
O-HO
1.94(2)
2.764(4)
168(3)
O-HN
1.901(18)
2.772(4)
175(4)
O-HN
2.043(18)
2.896(4)
173(4)
O-HN
2.07(2)
2.939(4)
173(4)
O-HN
2.02(2)
2.894(4)
169(5)
OLASAM.IPOAc.H2O
N-HO
2.03(3)
2.881(4)
160(4)
N-HO
2.068(2)
2.958(5)
177(6)
N-HO
1.94(3)
2.812(5)
161(6)
N-HO
1.90
2.620(5)
143.7
O-HO
2.061(1)
2.922(4)
173(4)
O-HO
2.08(3)
2.847(4)
146(5)
O-HO
1.924(1)
2.783(4)
172(4)
O-HO
2.142(2)
2.976(5)
162(4)
O-HO
1.890(2)
2.750(4)
168(4)
O-HN
2.16(2)
2.984(5)
160(4)
O-HN
1.926(1)
2.790(5)
176(5)
O-HN
2.049(2)
2.899(4)
167(5)
O-HN
Table 2: Selected hydrogen bond distances and parameters of cocrystals
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